

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 April 2011 (14.04.2011)

(10) International Publication Number  
WO 2011/044205 A1

(51) International Patent Classification:

C12Q 1/68 (2006.01)

SM, TR only): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(21) International Application Number:

PCT/US2010/051589

(72) Inventors; and

(75) Inventors/Applicants (for US only): BEHRENS, Timothy, W. [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US). GRAHAM, Robert, R. [US/US]; c/o Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 (US).

(22) International Filing Date:

6 October 2010 (06.10.2010)

(74) Agents: DAVIS, Jennifer, L. et al.; Genentech, Inc., 1 DNA Way, MS 49, South San Francisco, CA 94080 (US).

(25) Filing Language:

English

(76) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(26) Publication Language:

English

(30) Priority Data:

61/278,510 7 October 2009 (07.10.2009)

US

(71) Applicant (for all designated States except AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, US): GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080 (US).

(71) Applicant (for AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK,

[Continued on next page]

(54) Title: METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS




FIG. 1

(57) Abstract: Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. The methods provided are based on a set of alleles associated with systemic lupus erythematosus (SLE) risk loci including BLK, TNIP1, PRDM1, JAZF1, UHRF1BPI, IL1 O, IFI1H, CFB, CEC16A, IL12B and SH2B3 that contribute to SLE risk. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents.



**(84) Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

**METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS****CROSS REFERENCE TO RELATED APPLICATIONS**

**[0001]** This application claims the benefit of priority of provisional U.S. Application No. 61/278,510 filed October 7, 2009 which is hereby incorporated by reference in its entirety.

**SEQUENCE LISTING**

**[0002]** The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on September 20, 2010, is named P4325R1W.txt and is 3,576 bytes in size.

**FIELD**

**[0003]** Methods of identifying, diagnosing, prognosing, and assessing risk of developing lupus are provided, as well as methods of treating lupus. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents.

**BACKGROUND**

**[0004]** Lupus is an autoimmune disease that is estimated to affect nearly 1 million Americans, primarily women between the ages of 20-40. Lupus involves antibodies that attack connective tissue. The principal form of lupus is a systemic one (systemic lupus erythematosus; SLE). SLE is a chronic autoimmune disease with strong genetic as well as environmental components (See, *e.g.*, Hochberg MC, Dubois' Lupus Erythematosus. 5th ed., Wallace DJ, Hahn BH, eds. Baltimore: Williams and Wilkins (1997); Wakeland EK, et al., Immunity 2001;15(3):397-408; Nath SK, et al., Curr. Opin. Immunol. 2004;16(6):794-800; D'Cruz et al., Lancet (2007), 369:587-596). Various additional forms of lupus are known, including, but not limited to, cutaneous lupus erythematosus (CLE), lupus nephritis (LN), and neonatal lupus.

**[0005]** Untreated lupus can be fatal as it progresses from attack of skin and joints to internal organs, including lung, heart, and kidneys (with renal disease being the primary concern), thus making early and accurate diagnosis of and/or assessment of risk of developing

lupus particularly critical. Lupus mainly appears as a series of flare-ups, with intervening periods of little or no disease manifestation. Kidney damage, measured by the amount of proteinuria in the urine, is one of the most acute areas of damage associated with pathogenicity in SLE, and accounts for at least 50% of the mortality and morbidity of the disease.

**[0006]** Clinically, SLE is a heterogeneous disorder characterized by high-affinity autoantibodies (autoAbs). AutoAbs play an important role in the pathogenesis of SLE, and the diverse clinical manifestations of the disease are due to the deposition of antibody-containing immune complexes in blood vessels leading to inflammation in the kidney, brain and skin. AutoAbs also have direct pathogenic effects contributing to hemolytic anemia and thrombocytopenia. SLE is associated with the production of antinuclear antibodies, circulating immune complexes, and activation of the complement system. SLE has an incidence of about 1 in 700 women between the ages of 20 and 60. SLE can affect any organ system and can cause severe tissue damage. Numerous autoAbs of differing specificity are present in SLE. SLE patients often produce autoAbs having anti-DNA, anti-Ro, and anti-platelet specificity and that are capable of initiating clinical features of the disease, such as glomerulonephritis, arthritis, serositis, complete heart block in newborns, and hematologic abnormalities. These autoAbs are also possibly related to central nervous system disturbances. Arbuckle *et al.* described the development of autoAbs before the clinical onset of SLE (Arbuckle et al. N. Engl. J. Med. 349(16): 1526-1533 (2003)). Definitive diagnosis of lupus, including SLE, is not easy, resulting in clinicians resorting to a multi-factorial signs and symptoms-based classification approach (Gill et al., American Family Physician 68(11): 2179-2186(2003)).

**[0007]** One of the most difficult challenges in clinical management of complex autoimmune diseases such as lupus is the accurate and early identification of the disease in a patient. Over the years, many linkage and candidate gene studies have been performed to identify genetic factors contributing to SLE susceptibility. Haplotypes carrying the HLA Class II alleles DRB1\*0301 and DRB1\*1501 are clearly associated with disease as well as the presence of antibodies to nuclear autoantigens. *See, e.g.*, Goldberg MA, et al., Arthritis Rheum. 19(2):129-32 (1976); Graham RR, et al., Am J Hum Genet. 71(3):543-53 (2002); and Graham RR, et al., Eur J Hum Genet. 15(8):823-30 (2007). More recently, variants of Interferon Regulatory Factor 5 (IRF5) and Signal Transducer and Activator of Transcription 4 (STAT4) were discovered to be significant risk factors for SLE. *See, e.g.*, Sigurdsson S, et

al., Am J Hum Genet. 76(3):528-37 (2005); Graham RR, et al., Nat Genet. 38(5):550-55 (2006); Graham RR, et al., Proc Natl Acad Sci USA 104(16):6758-63 (2007); and Remmers EF, et al., N Engl J Med. 357(10):977-86 (2007). The identification of IRF5 and STAT4 as SLE risk genes provides support for the concept that, in certain instances, the type I interferon (IFN) pathway plays an important role in SLE disease pathogenesis. Type I IFN is present in serum of SLE cases, and production of IFN is linked to the presence of Ab and nucleic acid containing immune complexes (reviewed in Ronnblom et al., J Exp Med 194:F59 (2001); see also Baechler EC, et al., Curr Opin Immunol. 16(6):801-07 (2004); Banchereau J, et al., Immunity 25(3):383-92 (2006); Miyagi et al., J Exp Med 204(10):2383-96 (2007)). The majority of SLE cases exhibit a prominent type I IFN gene expression ‘signature’ in blood cells (Baechler et al., Proc Natl Acad Sci USA 100:2610 (2003); Bennett et al., J Exp Med 197:711 (2003)) and have elevated levels of IFN-inducible cytokines and chemokines in serum (Bauer et al., PLoS Med 3:e491 (2006)). Immune complexes containing native DNA and RNA stimulate toll-like receptors (TLRs) 7 and 9 expressed by dendritic cells and B cells to produce type I interferon which further stimulates immune complex formation (reviewed in (Marshak-Rothstein et al., Annu Rev Immunol 25, 419 (2007)).

**[0008]** In addition, a number of studies have been performed to identify reliable biomarkers for diagnostic and prognostic purposes. No clinically validated diagnostic markers, however, e.g., biomarkers, have been identified that enable clinicians or others to accurately define pathophysiological aspects of SLE, clinical activity, response to therapy, prognosis, or risk of developing the disease, although a number of candidate genes and alleles (variants) have been identified that are thought to contribute to SLE susceptibility. For example, at least 13 common alleles that contribute risk for SLE in individuals of European ancestry have been reported (Kyogoku et al., Am J Hum Genet 75(3):504-7 (2004); Sigurdsson et al., Am J Hum Genet 76(3):528-37 (2005); Graham et al., Nat Genet 38(5):550-55 (2006); Graham et al., Proc Natl Acad Sci U S A 104(16):6758-63 (2007); Remmers et al., N Engl J Med 357(10):977-86 (2007); Cunningham Graham et al., Nat Genet 40(1):83-89 (2008); Harley et al., Nat Genet 40(2):204-10 (2008); Hom et al., N Engl J Med 358(9):900-9 (2008); Kozyrev et al., Nat Genet 40(2):211-6 (2008); Nath et al., Nat Genet 40(2):152-4 (2008); Sawalha et al., PLoS ONE 3(3):e1727 (2008)). The putative causal alleles are known for *HLA-DR3*, *HLA-DR2*, *FCGR2A*, *PTPN22*, *ITGAM* and *BANK1* (Kyogoku et al., Am J Hum Genet 75(3):504-7 (2004); Kozyrev et al., Nat Genet 40(2):211-6 (2008); Nath et al., Nat Genet 40(2):152-4 (2008)), while the risk haplotypes for *IRF5*,

*TNFSF4* and *BLK* likely contribute to SLE by influencing mRNA and protein expression levels (Sigurdsson et al., Am J Hum Genet 76(3):528-37 (2005); Graham et al., Nat Genet 38(5):550-55 (2006); Graham et al., Proc Natl Acad Sci U S A 104(16):6758-63 (2007); Cunningham Graham et al., Nat Genet 40(1):83-89 (2008); Hom et al., N Engl J Med 358(9):900-9 (2008)). The causal alleles for *STAT4*, *KIAA1542*, *IRAK1*, *PXK* and other genes, such as *BLK*, have not been determined (Remmers et al., N Engl J Med 357(10):977-86 (2007); Harley et al., Nat Genet 40(2):204-10 (2008); Hom et al., N Engl J Med 358(9):900-9 (2008); Sawalha et al., PLoS ONE 3(3):e1727 (2008)). These and other genetic variations associated with lupus are also described in Int'l Pat. Appl. No.

PCT/US2008/064430 (Int'l Pub. No. WO 2008/144761). While the contribution of such genetic variation to various aspects of SLE risk and disease that has been described to date has been important, more information about the contribution of genetic variation to, for example, the significant clinical heterogeneity of SLE remains to be determined.

**[0009]** It would therefore be highly advantageous to have additional molecular-based diagnostic methods that can be used to objectively identify the presence of and/or classify the disease in a patient, define pathophysiologic aspects of lupus, clinical activity, response to therapy, prognosis, and/or risk of developing lupus. In addition, it would be advantageous to have molecular-based diagnostic markers associated with various clinical and/or pathophysiological and/or other biological indicators of disease. Thus, there is a continuing need to identify new risk loci and polymorphisms associated with lupus as well as other autoimmune disorders. Such associations would greatly benefit the identification of the presence of lupus in patients or the determination of susceptibility to develop the disease. Such associations would also benefit the identification of pathophysiologic aspects of lupus, clinical activity, response to therapy, or prognosis. In addition, statistically and biologically significant and reproducible information regarding such associations could be utilized as an integral component in efforts to identify specific subsets of patients who would be expected to significantly benefit from treatment with a particular therapeutic agent, for example where the therapeutic agent is or has been shown in clinical studies to be of therapeutic benefit in such specific lupus patient subpopulation.

**[0010]** The invention described herein meets the above-described needs and provides other benefits.

**[0011]** All references cited herein, including patent applications and publications, are incorporated by reference in their entirety for any purpose.

## SUMMARY

**[0012]** The methods provided are based, at least in part, on the discovery of a set of novel loci that are associated with SLE and that contribute disease risk (SLE risk loci). In addition, a set of alleles associated with these SLE risk loci are provided. Also included is the causal allele within the *BLK* locus that is associated with biological effects that increase SLE risk. In addition, risk loci associated with other autoimmune diseases and increased SLE risk are provided.

**[0013]** In one aspect, a method of identifying lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in a SLE risk locus, wherein the SLE risk locus is *BLK*, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP), wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and wherein the subject is suspected of suffering from lupus. In one embodiment, the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

**[0014]** In another aspect, a method of identifying lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4, and wherein the subject is suspected of suffering from lupus. In certain embodiments, a variation is detected in at least two loci, or at least three loci, or at least four loci, or at least five loci, or at least ten loci, or at least 13 loci, or at 26 loci. In one embodiment, the at least one locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*. In one embodiment, the variation in the at least one locus comprises a SNP as set forth in Table 4. In certain embodiments, the presence of a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4, is detected in combination with the presence of a variation in the *BLK* SLE risk locus, wherein the variation in the *BLK* locus occurs at a nucleotide position

corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8. In one embodiment, the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

**[0015]** In still another aspect, a method of identifying lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6, and wherein the subject is suspected of suffering from lupus. In certain embodiments, a variation is detected in at least two loci, or at least three loci, or at least four loci, or at five loci. In one embodiment, the at least one locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In one embodiment, the variation in the at least one locus comprises a SNP as set forth in Table 6. In certain embodiments, the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6, is detected in combination with the presence of a variation in the *BLK* SLE risk locus, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8. In one embodiment, the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

**[0016]** In yet another aspect, a method of identifying lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 4 and the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in each locus occurs at a nucleotide position corresponding to the position of a SNP for each locus as set forth in Tables 4 and 6, respectively, and wherein the subject is suspected of suffering from lupus. In certain embodiments, a variation is detected in at least three loci, or at least four

loci, or at least five loci, or at least seven loci, or at least ten loci. In one embodiment, the at least one locus as set forth in Table 4 is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10* and the at least one locus as set forth in Table 6 is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In one embodiment, the variation in the at least one locus as set forth in Table 4 and the variation in the at least one locus as set forth in Table 6 comprises a SNP as set forth in Tables 4 and 6, respectively. In certain embodiments, the presence of a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4, and the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6, is detected in combination with the presence of a variation in the *BLK* SLE risk locus, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8. In one embodiment, the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

**[0017]** In one aspect, a method for predicting responsiveness of a subject with lupus to a lupus therapeutic agent is provided, the method comprising determining whether the subject comprises a variation in a SLE risk locus, wherein the SLE risk locus is *BLK*, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 82, wherein the presence of the variation in the *BLK* SLE risk locus indicates the responsiveness of the subject to the therapeutic agent.

**[0018]** In another aspect, a method for predicting responsiveness of a subject with lupus to a lupus therapeutic agent is provided, the method comprising determining whether the subject comprises a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4, wherein the presence of a variation in the at least one locus indicates the responsiveness of the subject to the therapeutic agent.

In certain embodiments, the subject comprises a variation in at least two loci, or at least three loci, or at least four loci, or at least five loci, or at least ten loci, or at least 13 loci, or at 26 loci. In one embodiment, the at least one locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*. In one embodiment, the variation in the at least one locus comprises a SNP as set forth in Table 4. In certain embodiments, the method comprises determining whether the subject comprises a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4, in combination with a variation in the *BLK* SLE risk locus, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, wherein the presence of a variation in the at least one locus as set forth in Table 4 and the presence of the variation in the *BLK* locus indicates the responsiveness of the subject to the therapeutic agent.

**[0019]** In still another aspect, a method for predicting responsiveness of a subject with lupus to a lupus therapeutic agent is provided, the method comprising determining whether the subject comprises a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6, wherein the presence of a variation in the at least one locus indicates the responsiveness of the subject to the therapeutic agent. In certain embodiments, the subject comprises a variation in at least two loci, or at least three loci, or at least four loci, or at five loci. In one embodiment, the at least one locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In one embodiment, the variation in the at least one locus comprises a SNP as set forth in Table 6. In certain embodiments, the method comprises determining whether the subject comprises a variation in at least SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6, in combination with a variation in the *BLK* SLE risk locus, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, wherein the presence of a variation in the at least one locus as set forth in Table 6 and the presence of the variation in the *BLK* locus indicates the responsiveness of the subject to the therapeutic agent.

**[0020]** In a further aspect, a method for predicting responsiveness of a subject with lupus to a lupus therapeutic agent is provided, the method comprising determining whether the subject comprises a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4, and a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6, wherein the presence of a variation in the at least one locus as set forth in Table 4 and the presence of a variation in the at least one locus as set forth in Table 6 indicates the responsiveness of the subject to the therapeutic agent. In certain embodiments, the subject comprises a variation in at least three loci, or at least four loci, or at least five loci, or at least seven loci, or at least ten loci. In one embodiment, the at least one locus as set forth in Table 4 is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10* and the at least one locus as set forth in Table 6 is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In one embodiment, the variation in the at least one locus as set forth in Table 4 and the at least one locus as set forth in Table 6 comprises a SNP as set forth in Tables 4 and 6, respectively. In certain embodiments, the method comprises determining whether the subject comprises a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4, and a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6, in combination with a variation in the *BLK* SLE risk locus, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, wherein the presence of a variation in the at least one locus as set forth in Table 4 and the presence of a variation in the at least one locus as set forth in Table 6 and the presence of the variation in the *BLK* locus indicates the responsiveness of the subject to the therapeutic agent.

**[0021]** In yet another aspect, a method of diagnosing or prognosing lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in a SLE risk locus, wherein the SLE risk locus is *BLK*, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of

a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

**[0022]** In yet a further aspect, a method of diagnosing or prognosing lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 4, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4; the variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 4; and the presence of the variation in the at least one locus is a diagnosis or prognosis of lupus in the subject. In certain embodiments, a variation is detected in at least two loci, or at least three loci, or at least four loci, or at least five loci, or at least ten loci, or at least 13 loci, or at 26 loci. In one embodiment, the at least one SLE risk locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*. In certain embodiments, the method comprises detecting the presence of a variation in at least one SLE risk locus as set forth in Table 4 in combination with the presence of a variation in the *BLK* SLE risk locus, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4 and a variation in the *BLK* locus, the variation in the at least one locus as set forth in Table 4 comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 4, and the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and the presence of the variation in the at least one locus as set forth in Table 4 and the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

**[0023]** In a still further aspect, a method of diagnosing or prognosing lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 6; the variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6; and the presence of the variation in the at least one locus is a diagnosis or prognosis of lupus in the subject. In certain embodiments, a variation is detected in at least

two loci, or at least three loci, or at least four loci, or at five loci. In one embodiment, the at least one SLE risk locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In certain embodiments, the method comprises detecting the presence of a variation in at least one SLE risk locus as set forth in Table 6 in combination with the presence of a variation in the *BLK* SLE risk locus, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 6 and a variation in the *BLK* locus, the variation in the at least one locus as set forth in Table 6 comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6, and the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and the presence of the variation in the at least one locus as set forth in Table 6 and the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

**[0024]** In yet another aspect, a method of diagnosing or prognosing lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 4 and the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4 and a variation in at least one SLE risk locus as set forth in Table 6; the variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Tables 4 and 6, respectively; and the presence of the variation in the at least one locus as set forth in Table 4 and the presence of the variation in the at least one locus as set forth in Table 6 is a diagnosis or prognosis of lupus in the subject. In certain embodiments, a variation is detected in at least three loci, or at least four loci, or at least five loci, or at least seven loci, or at least ten loci. In one embodiment, the at least one SLE risk locus as set forth in Table 4 is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10* and the at least one SLE risk locus as set forth in Table 6 is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In certain embodiments, the method comprises detecting the presence of a variation in at least one SLE risk locus as set forth in Table 4 and the presence of a variation in at least one SLE risk locus as set forth in Table 6 in combination with the presence of a variation in the *BLK* SLE risk locus, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4 and

variation in at least SLE risk locus as set forth in Table 6 and a variation in the *BLK* locus, the variation in the at least one locus as set forth in Table 4 comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 4, and the variation in the at least one locus as set forth in Table 6 comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6, and the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and the presence of the variation in the at least one locus as set forth in Table 4 and the presence of the variation in the at least one locus as set forth in Table 6 and the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

**[0025]** In another aspect, a method of aiding in the diagnosis or prognosis of lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in a SLE risk locus, wherein the SLE risk locus is *BLK*, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

**[0026]** In yet another aspect, a method of aiding in the diagnosis or prognosis of lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 4, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4; the variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 4; and the presence of the variation in the at least one locus is a diagnosis or prognosis of lupus in the subject. In certain embodiments, a variation is detected in at least two loci, or at least three loci, or at least four loci, or at least five loci, or at least ten loci, or at least 13 loci, or at 26 loci. In one embodiment, the at least one SLE risk locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*. In certain embodiments, the method comprises detecting the presence of a variation in at least one SLE risk locus as set forth in Table 4 in combination with the presence of a variation in the *BLK* SLE risk locus, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4 and a

variation in the *BLK* locus, the variation in the at least one locus as set forth in Table 4 comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 4, and the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and the presence of the variation in the at least one locus as set forth in Table 4 and the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

**[0027]** In a still further aspect, a method of aiding in the diagnosis or prognosis of lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 6; the variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6; and the presence of the variation in the at least one locus is a diagnosis or prognosis of lupus in the subject. In certain embodiments, a variation is detected in at least two loci, or at least three loci, or at least four loci, or at five loci. In one embodiment, the at least one SLE risk locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In certain embodiments, the method comprises detecting the presence of a variation in at least one SLE risk locus as set forth in Table 6 in combination with the presence of a variation in the *BLK* SLE risk locus, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 6 and a variation in the *BLK* locus, the variation in the at least one locus as set forth in Table 6 comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6, and the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and the presence of the variation in the at least one locus as set forth in Table 6 and the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

**[0028]** In yet a further aspect, a method of aiding in the diagnosis or prognosis of lupus in a subject is provided, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 4 and the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein: the

biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4 and a variation in at least one SLE risk locus as set forth in Table 6; the variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Tables 4 and 6, respectively; and the presence of the variation in the at least one locus as set forth in Table 4 and the presence of the variation in the at least one locus as set forth in Table 6 is a diagnosis or prognosis of lupus in the subject. In certain embodiments, a variation is detected in at least three loci, or at least four loci, or at least five loci, or at least seven loci, or at least ten loci. In one embodiment, the at least one SLE risk locus as set forth in Table 4 is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10* and the at least one SLE risk locus as set forth in Table 6 is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In certain embodiments, the method comprises detecting the presence of a variation in at least one SLE risk locus as set forth in Table 4 and the presence of a variation in at least one SLE risk locus as set forth in Table 6 in combination with the presence of a variation in the *BLK* SLE risk locus, wherein: the biological sample is known to comprise, or suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4 and variation in at least one SLE risk locus as set forth in Table 6 and a variation in the *BLK* locus, the variation in the at least one locus as set forth in Table 4 comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 4, and the variation in the at least one locus as set forth in Table 6 comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6, and the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a SNP, wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and the presence of the variation in the at least one locus as set forth in Table 4 and the presence of the variation in the at least one locus as set forth in Table 6 and the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

**[0029]** In one aspect, a method of treating a lupus condition in a subject is provided, wherein a genetic variation is known to be present at a nucleotide position corresponding to a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, the method comprising administering to the subject a therapeutic agent effective to treat the condition.

**[0030]** In another aspect, a method of treating a lupus condition in a subject in whom a genetic variation is known to be present at a nucleotide position corresponding to a SNP as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4 is provided, the method comprising administering to the subject a therapeutic agent effective to treat the condition. In one embodiment, the at least one SLE risk locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*.

**[0031]** In another aspect, a method of treating a lupus condition in a subject in whom a genetic variation is known to be present at a nucleotide position corresponding to a SNP as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6 is provided, the method comprising administering to the subject a therapeutic agent effective to treat the condition. In one embodiment, the at least one SLE risk locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B30*.

**[0032]** In another aspect, a method of treating a subject having a lupus condition is provided, the method comprising administering to the subject a therapeutic agent effective to treat the condition in a subject who has a genetic variation at a nucleotide position corresponding to a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

**[0033]** In yet another aspect, a method of treating a subject having a lupus condition is provided, the method comprising administering to the subject a therapeutic agent effective to treat the condition in a subject who has a genetic variation at a nucleotide position corresponding to a SNP as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4. In one embodiment, the at least one SLE risk locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*.

**[0034]** In still yet another aspect, a method of treating a subject having a lupus condition is provided, the method comprising administering to the subject a therapeutic agent effective to treat the condition in a subject who has a genetic variation at a nucleotide position corresponding to a SNP as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6. In one embodiment, the at least one SLE risk locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.

**[0035]** In yet another aspect, a method of treating a subject having a lupus condition is provided, the method comprising administering to the subject a therapeutic agent shown to be effective to treat said condition in at least one clinical study wherein the agent was

administered to at least five human subjects who each had a genetic variation at a nucleotide position corresponding to a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

**[0036]** In still yet another aspect, a method of treating a subject having a lupus condition is provided, the method comprising administering to the subject a therapeutic agent shown to be effective to treat said condition in at least one clinical study wherein the agent was administered to at least five human subjects who each had a genetic variation at a nucleotide position corresponding to a SNP as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4. In one embodiment, the at least one SLE risk locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*.

**[0037]** In yet another aspect, a method of treating a subject having a lupus condition is provided, the method comprising administering to the subject a therapeutic agent shown to be effective to treat said condition in at least one clinical study wherein the agent was administered to at least five human subjects who each had a genetic variation at a nucleotide position corresponding to a SNP as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6. In one embodiment, the at least one SLE risk locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.

**[0038]** In another aspect, a method comprising manufacturing a lupus therapeutic agent is provided, which includes packaging the agent with instructions to administer the agent to a subject who has or is believed to have lupus and who has a genetic variation at a position corresponding to a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

**[0039]** In yet another aspect, a method comprising manufacturing a lupus therapeutic agent is provided, which includes packaging the agent with instructions to administer the agent to a subject who has or is believed to have lupus and who has a genetic variation at a position corresponding to a SNP as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4.

**[0040]** In yet a further aspect, a method comprising manufacturing a lupus therapeutic agent is provided, which includes packaging the agent with instructions to administer the agent to a subject who has or is believed to have lupus and who has a genetic variation at a

position corresponding to a SNP as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6.

**[0041]** In one aspect, a method for selecting a patient suffering from lupus for treatment with a lupus therapeutic agent is provided, the method comprising detecting the presence of a genetic variation at a nucleotide position corresponding to a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8. In one embodiment, the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

**[0042]** In a further aspect, a method for selecting a patient suffering from lupus for treatment with a lupus therapeutic agent is provided, the method comprising detecting the presence of a genetic variation at a nucleotide position corresponding to a SNP as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4. In certain embodiments, a variation is detected in at least two loci, or at least three loci, or at least four loci, or at least five loci, or at least ten loci, or at least 13 loci, or at 26 loci. In one embodiment, the at least one SLE risk locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*. In one embodiment, the variation at the least one locus comprises a SNP as set forth Table 4. In one embodiment, the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

**[0043]** In a further aspect, a method for selecting a patient suffering from lupus for treatment with a lupus therapeutic agent is provided, the method comprising detecting the presence of a genetic variation at a nucleotide position corresponding to a SNP as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6. In certain embodiments, a variation is detected in at least two loci, or at least three loci, or at least four loci, or at five loci. In one embodiment, the at least one SLE risk locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In one embodiment, the variation at the least one locus comprises a SNP as set forth Table 6. In one embodiment, the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide

hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

**[0044]** In another aspect, a method of assessing whether a subject is at risk of developing lupus is provided, the method comprising detecting in a biological sample obtained from the subject, the presence of a genetic signature indicative of risk of developing lupus, wherein said genetic signature comprises a set of at least three SNPs, each SNP occurring in a SLE risk locus as set forth in Table 4 and/or Table 6. In certain embodiments, the genetic signature comprises a set of at least four SNPs, or at least five SNPs, or at least seven SNPs, or at least ten SNPs. In one embodiment, the SLE risk loci are selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, *IL10*, *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In certain embodiments, the genetic signature further comprises a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

**[0045]** In a further aspect, a method of diagnosing lupus in a subject is provided, the method comprising detecting in a biological sample obtained from said subject, the presence of a genetic signature indicative of lupus, wherein said genetic signature comprises a set of at least three SNPs, each SNP occurring in a SLE risk locus as set forth in Table 4 and/or Table 6. In certain embodiments, the genetic signature comprises a set of at least four SNPs, or at least five SNPs, or at least seven SNPs, or at least ten SNPs, or at least 15 SNPs, or at least 20 SNPs, or at least 30 SNPs. In one embodiment, the SLE risk loci are selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, *IL10*, *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*. In certain embodiments, the genetic signature further comprises a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

## BRIEF DESCRIPTION OF THE DRAWINGS

**[0046]** Figure 1 shows an overview of the experimental design for the targeted replication study of certain SNPs to identify additional SLE risk loci as described in Example 1.

**[0047]** Figure 2 shows novel genome-wide significant associations in SLE and the identification of novel risk loci within *TNIP1* (A), *PRDM1* (B), *JAZF1* (C), *UHRF1BP1* (D), and *IL10* (E) as described in Example 1. (F) A histogram of the P values of independent SNPs in the case and control replication samples as described in Example 1; the expected density of results under a null distribution is indicated by the dashed line.

[0048] Figure 3 shows the percentage of variants reaching candidate ( $P < 1 \times 10^{-5}$ ) and confirmed ( $P < 5 \times 10^{-8}$ ) status in the meta-analysis stratified by the P value in the original GWAS as described in Example 1.

[0049] Figure 4 shows a linkage disequilibrium block (shown in  $r^2$ ) within the *BLK* promoter region as described in Example 2. Figure 4 discloses 'C>T-rs922483' as SEQ ID NO: 13.

[0050] Figure 5 shows the results of luciferase reporter gene expression assays of the *BLK* promoter region having various haplotypes as described in Example 2. (A) SNP rs922483 C>T (SEQ ID NO: 13) in BJAB cells; (B) SNP rs922483 C>T (SEQ ID NO: 13) in Daudi cells; (C) SNP rs1382568 A>C/G>C in BJAB cells; (D) SNP rs1382568 A>C/G>C in Daudi cells; (E) SNP rs4840568 G>A in BJAB cells; (F) SNP rs4840568 G>A in Daudi cells; data shown represent the mean +/- standard error of the mean in triplicate assays; spotted bars show the results for the haplotype indicated to the left of the graph; hatched bar: risk haplotype 22-ACT; open bar: non-risk haplotype 22-GAC; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , ns=not significant (t-test). Figures 5A-F disclose '22 (GT) repeat' as SEQ ID NO: 15. Figures 5C-F also disclose 'rs922483 C>T' as SEQ ID NO: 13.

[0051] Figure 6 shows the results of luciferase reporter gene expression assays of the *BLK* promoter region having either 18 (GT) repeats (SEQ ID NO: 14) or 22 (GT) repeats (SEQ ID NO: 15) and the SNP rs1382568 A>C/G>C in Daudi cells as described in Example 2. Data shown represent the mean +/- standard error of the mean in duplicate assays; ns=not significant (t-test). Figure 6 discloses '18 (GT) repeat' as SEQ ID NO: 14, '22 (GT) repeat' as SEQ ID NO: 15, and 'rs922483 C>T' as SEQ ID NO: 13.

[0052] Figure 7 shows the sequence of the SNP, rs922483 (SEQ ID NO: 13), and the location within the SNP of the causal allele for the *BLK* locus as described in Example 2. The location of the causal allele is shown by bold brackets; the C/T variations are indicated in bold.

## DETAILED DESCRIPTION

[0053] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook et al., 1989); "Oligonucleotide Synthesis"

(M. J. Gait, ed., 1984); "Animal Cell Culture" (R. I. Freshney, ed., 1987); "Methods in Enzymology" (Academic Press, Inc.); "Current Protocols in Molecular Biology" (F. M. Ausubel et al., eds., 1987, and periodic updates); "PCR: The Polymerase Chain Reaction", (Mullis et al., eds., 1994). In addition, primers, oligonucleotides and polynucleotides employed in the present invention can be generated using standard techniques known in the art.

**[0054]** Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. For example, Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, N.Y. 1994), and March, Advanced Organic Chemistry Reactions, Mechanisms and Structure 4th ed., John Wiley & Sons (New York, N.Y. 1992), provide one skilled in the art with a general guide to many of the terms used in the present application.

## DEFINITIONS

**[0055]** For purposes of interpreting this specification, the following definitions will apply and whenever appropriate, terms used in the singular will also include the plural and vice versa. As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a protein" includes a plurality of proteins; reference to "a cell" includes mixtures of cells, and the like. In the event that any definition set forth below conflicts with any document incorporated herein by reference, the definition set forth below shall control.

**[0056]** "Lupus" or "lupus condition", as used herein is an autoimmune disease or disorder that in general involves antibodies that attack connective tissue. The principal form of lupus is a systemic one, systemic lupus erythematosus (SLE), including cutaneous SLE and subacute cutaneous SLE, as well as other types of lupus (including nephritis, extrarenal, cerebritis, pediatric, non-renal, discoid, and alopecia).

**[0057]** The term "polynucleotide" or "nucleic acid," as used interchangeably herein, refers to polymers of nucleotides of any length, and include DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be

imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. Other types of modifications include, for example, "caps", substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, cabamates, etc.) and with charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), those containing pendant moieties, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), those with intercalators (e.g., acridine, psoralen, etc.), those containing chelators (e.g., metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotide(s). Further, any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid supports. The 5' and 3' terminal OH can be phosphorylated or substituted with amines or organic capping groups moieties of from 1 to 20 carbon atoms. Other hydroxyls may also be derivatized to standard protecting groups. Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2'-O-methyl-2'-O- allyl, 2'-fluoro- or 2'-azido-ribose, carbocyclic sugar analogs,  $\alpha$ - anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs and abasic nucleoside analogs such as methyl riboside. One or more phosphodiester linkages may be replaced by alternative linking groups. These alternative linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(O)S("thioate"), P(S)S ("dithioate"), "(O)NR<sub>2</sub> ("amide"), P(O)R, P(O)OR', CO or CH<sub>2</sub> ("formacetal"), in which each R or R' is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (---O---) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or araldyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.

**[0058]** "Oligonucleotide," as used herein, refers to short, single stranded polynucleotides that are at least about seven nucleotides in length and less than about 250 nucleotides in length. Oligonucleotides may be synthetic. The terms "oligonucleotide" and

"polynucleotide" are not mutually exclusive. The description above for polynucleotides is equally and fully applicable to oligonucleotides.

**[0059]** The term "primer" refers to a single stranded polynucleotide that is capable of hybridizing to a nucleic acid and allowing the polymerization of a complementary nucleic acid, generally by providing a free 3'-OH group.

**[0060]** The term "genetic variation" or "nucleotide variation" refers to a change in a nucleotide sequence (e.g., an insertion, deletion, inversion, or substitution of one or more nucleotides, such as a single nucleotide polymorphism (SNP)) relative to a reference sequence (e.g., a commonly-found and/or wild-type sequence, and/or the sequence of a major allele). The term also encompasses the corresponding change in the complement of the nucleotide sequence, unless otherwise indicated. In one embodiment, a genetic variation is a somatic polymorphism. In one embodiment, a genetic variation is a germline polymorphism.

**[0061]** A "single nucleotide polymorphism", or "SNP", refers to a single base position in DNA at which different alleles, or alternative nucleotides, exist in a population. The SNP position is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations). An individual may be homozygous or heterozygous for an allele at each SNP position.

**[0062]** The term "amino acid variation" refers to a change in an amino acid sequence (e.g., an insertion, substitution, or deletion of one or more amino acids, such as an internal deletion or an N- or C-terminal truncation) relative to a reference sequence.

**[0063]** The term "variation" refers to either a nucleotide variation or an amino acid variation.

**[0064]** The term "a genetic variation at a nucleotide position corresponding to the position of a SNP," "a nucleotide variation at a nucleotide position corresponding to the position of a SNP," and grammatical variants thereof refer to a nucleotide variation in a polynucleotide sequence at the relative corresponding DNA position occupied by said SNP in the genome. The term also encompasses the corresponding variation in the complement of the nucleotide sequence, unless otherwise indicated.

**[0065]** The term "array" or "microarray" refers to an ordered arrangement of hybridizable array elements, preferably polynucleotide probes (e.g., oligonucleotides), on a substrate. The substrate can be a solid substrate, such as a glass slide, or a semi-solid substrate, such as nitrocellulose membrane.

**[0066]** The term "amplification" refers to the process of producing one or more copies of a reference nucleic acid sequence or its complement. Amplification may be linear or exponential (e.g., PCR). A "copy" does not necessarily mean perfect sequence complementarity or identity relative to the template sequence. For example, copies can include nucleotide analogs such as deoxyinosine, intentional sequence alterations (such as sequence alterations introduced through a primer comprising a sequence that is hybridizable, but not fully complementary, to the template), and/or sequence errors that occur during amplification.

**[0067]** The term "allele-specific oligonucleotide" refers to an oligonucleotide that hybridizes to a region of a target nucleic acid that comprises a nucleotide variation (generally a substitution). "Allele-specific hybridization" means that, when an allele-specific oligonucleotide is hybridized to its target nucleic acid, a nucleotide in the allele-specific oligonucleotide specifically base pairs with the nucleotide variation. An allele-specific oligonucleotide capable of allele-specific hybridization with respect to a particular nucleotide variation is said to be "specific for" that variation.

**[0068]** The term "allele-specific primer" refers to an allele-specific oligonucleotide that is a primer.

**[0069]** The term "primer extension assay" refers to an assay in which nucleotides are added to a nucleic acid, resulting in a longer nucleic acid, or "extension product," that is detected directly or indirectly. The nucleotides can be added to extend the 5' or 3' end of the nucleic acid.

**[0070]** The term "allele-specific nucleotide incorporation assay" refers to a primer extension assay in which a primer is (a) hybridized to target nucleic acid at a region that is 3' or 5' of a nucleotide variation and (b) extended by a polymerase, thereby incorporating into the extension product a nucleotide that is complementary to the nucleotide variation.

**[0071]** The term "allele-specific primer extension assay" refers to a primer extension assay in which an allele-specific primer is hybridized to a target nucleic acid and extended.

**[0072]** The term "allele-specific oligonucleotide hybridization assay" refers to an assay in which (a) an allele-specific oligonucleotide is hybridized to a target nucleic acid and (b) hybridization is detected directly or indirectly.

**[0073]** The term "5' nuclease assay" refers to an assay in which hybridization of an allele-specific oligonucleotide to a target nucleic acid allows for nucleolytic cleavage of the hybridized probe, resulting in a detectable signal.

**[0074]** The term “assay employing molecular beacons” refers to an assay in which hybridization of an allele-specific oligonucleotide to a target nucleic acid results in a level of detectable signal that is higher than the level of detectable signal emitted by the free oligonucleotide.

**[0075]** The term “oligonucleotide ligation assay” refers to an assay in which an allele-specific oligonucleotide and a second oligonucleotide are hybridized adjacent to one another on a target nucleic acid and ligated together (either directly or indirectly through intervening nucleotides), and the ligation product is detected directly or indirectly.

**[0076]** The term “target sequence,” “target nucleic acid,” or “target nucleic acid sequence” refers generally to a polynucleotide sequence of interest in which a nucleotide variation is suspected or known to reside, including copies of such target nucleic acid generated by amplification.

**[0077]** The term "detection" includes any means of detecting, including direct and indirect detection.

**[0078]** The term “SLE risk locus” and “confirmed SLE risk locus” refer to any one of the loci indicated in Table 4 and Table 6 and the *BLK* locus.

**[0079]** The term “SLE risk allele” and “confirmed SLE risk allele” refer to a variation occurring in a SLE risk locus. Such variations include, but are not limited to, single nucleotide polymorphisms, insertions, and deletions. Certain exemplary SLE risk alleles are indicated in Table 4 and in Table 6.

**[0080]** As used herein, a subject “at risk” of developing lupus may or may not have detectable disease or symptoms of disease, and may or may not have displayed detectable disease or symptoms of disease prior to the treatment methods described herein. “At risk” denotes that a subject has one or more risk factors, which are measurable parameters that correlate with development of lupus, as described herein and known in the art. A subject having one or more of these risk factors has a higher probability of developing lupus than a subject without one or more of these risk factor(s).

**[0081]** The term "diagnosis" is used herein to refer to the identification or classification of a molecular or pathological state, disease or condition. For example, “diagnosis” may refer to identification of a particular type of lupus condition, e.g., SLE. “Diagnosis” may also refer to the classification of a particular sub-type of lupus, e.g., by tissue/organ involvement (e.g., lupus nephritis), by molecular features (e.g., a patient subpopulation characterized by genetic variation(s) in a particular gene or nucleic acid region.)

**[0082]** The term "aiding diagnosis" is used herein to refer to methods that assist in making a clinical determination regarding the presence, or nature, of a particular type of symptom or condition of lupus. For example, a method of aiding diagnosis of lupus can comprise measuring the presence of absence of one or more SLE risk loci or SLE risk alleles in a biological sample from an individual.

**[0083]** The term "prognosis" is used herein to refer to the prediction of the likelihood of autoimmune disorder-attributable disease symptoms, including, for example, recurrence, flaring, and drug resistance, of an autoimmune disease such as lupus. The term "prediction" is used herein to refer to the likelihood that a patient will respond either favorably or unfavorably to a drug or set of drugs.

**[0084]** As used herein, "treatment" refers to clinical intervention in an attempt to alter the natural course of the individual or cell being treated, and can be performed before or during the course of clinical pathology. Desirable effects of treatment include preventing the occurrence or recurrence of a disease or a condition or symptom thereof, alleviating a condition or symptom of the disease, diminishing any direct or indirect pathological consequences of the disease, decreasing the rate of disease progression, ameliorating or palliating the disease state, and achieving remission or improved prognosis. In some embodiments, methods and compositions of the invention are useful in attempts to delay development of a disease or disorder.

**[0085]** An "effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. A "therapeutically effective amount" of a therapeutic agent may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the antibody to elicit a desired response in the individual. A therapeutically effective amount is also one in which any toxic or detrimental effects of the therapeutic agent are outweighed by the therapeutically beneficial effects. A "prophylactically effective amount" refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount.

**[0086]** An "individual," "subject" or "patient" is a vertebrate. In certain embodiments, the vertebrate is a mammal. Mammals include, but are not limited to, primates (including

human and non-human primates) and rodents (e.g., mice and rats). In certain embodiments, a mammal is a human.

**[0087]** A “patient subpopulation,” and grammatical variations thereof, as used herein, refers to a patient subset characterized as having one or more distinctive measurable and/or identifiable characteristics that distinguishes the patient subset from others in the broader disease category to which it belongs. Such characteristics include disease subcategories (e.g., SLE, lupus nephritis), gender, lifestyle, health history, organs/tissues involved, treatment history, etc.

**[0088]** A “control subject” refers to a healthy subject who has not been diagnosed as having lupus or a lupus condition and who does not suffer from any sign or symptom associated with lupus or a lupus condition.

**[0089]** The term “sample”, as used herein, refers to a composition that is obtained or derived from a subject of interest that contains a cellular and/or other molecular entity that is to be characterized and/or identified, for example based on physical, biochemical, chemical and/or physiological characteristics. For example, the phrases “biological sample” or “disease sample” and variations thereof refers to any sample obtained from a subject of interest that would be expected or is known to contain the cellular and/or molecular entity that is to be characterized.

**[0090]** By "tissue or cell sample" is meant a collection of similar cells obtained from a tissue of a subject or patient. The source of the tissue or cell sample may be solid tissue as from a fresh, frozen and/or preserved organ or tissue sample or biopsy or aspirate; blood or any blood constituents; bodily fluids such as cerebral spinal fluid, amniotic fluid, peritoneal fluid, or interstitial fluid; cells from any time in gestation or development of the subject. The tissue sample may also be primary or cultured cells or cell lines. Optionally, the tissue or cell sample is obtained from a disease tissue/organ. The tissue sample may contain compounds which are not naturally intermixed with the tissue in nature such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, or the like. A “reference sample”, “reference cell”, “reference tissue”, “control sample”, “control cell”, or “control tissue”, as used herein, refers to a sample, cell or tissue obtained from a source known, or believed, not to be afflicted with the disease or condition for which a method or composition of the invention is being used to identify. In one embodiment, a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy part of the body of the same subject or patient in whom a disease or condition is being identified

using a composition or method of the invention. In one embodiment, a reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from a healthy part of the body of an individual who is not the subject or patient in whom a disease or condition is being identified using a composition or method of the invention.

**[0091]** For the purposes herein a "section" of a tissue sample is meant a single part or piece of a tissue sample, *e.g.* a thin slice of tissue or cells cut from a tissue sample. It is understood that multiple sections of tissue samples may be taken and subjected to analysis according to the present invention, provided that it is understood that the present invention comprises a method whereby the same section of tissue sample is analyzed at both morphological and molecular levels, or is analyzed with respect to both protein and nucleic acid.

**[0092]** By "correlate" or "correlating" is meant comparing, in any way, the performance and/or results of a first analysis or protocol with the performance and/or results of a second analysis or protocol. For example, one may use the results of a first analysis or protocol in carrying out a second protocols and/or one may use the results of a first analysis or protocol to determine whether a second analysis or protocol should be performed. With respect to the embodiment of gene expression analysis or protocol, one may use the results of the gene expression analysis or protocol to determine whether a specific therapeutic regimen should be performed.

**[0093]** The word "label" when used herein refers to a compound or composition which is conjugated or fused directly or indirectly to a reagent such as a nucleic acid probe or an antibody and facilitates detection of the reagent to which it is conjugated or fused. The label may itself be detectable (*e.g.*, radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.

**[0094]** A "medicament" is an active drug to treat a disease, disorder, and/or condition. In one embodiment, the disease, disorder, and/or condition is lupus or its symptoms or side effects.

**[0095]** The term "increased resistance" to a particular therapeutic agent or treatment option, when used in accordance with the invention, means decreased response to a standard dose of the drug or to a standard treatment protocol.

**[0096]** The term "decreased sensitivity" to a particular therapeutic agent or treatment option, when used in accordance with the invention, means decreased response to a standard

dose of the agent or to a standard treatment protocol, where decreased response can be compensated for (at least partially) by increasing the dose of agent, or the intensity of treatment.

**[0097]** "Predicting response" of a subject, and variations thereof, can be assessed using any endpoint indicating a benefit to the patient, including, without limitation, (1) inhibition, to some extent, of disease progression, including slowing down and complete arrest; (2) reduction in the number of disease episodes and/or symptoms; (3) reduction in lesional size; (4) inhibition (i.e., reduction, slowing down or complete stopping) of disease cell infiltration into adjacent peripheral organs and/or tissues; (5) inhibition (i.e. reduction, slowing down or complete stopping) of disease spread; (6) decrease of auto-immune response, which may, but does not have to, result in the regression or ablation of the disease lesion; (7) relief, to some extent, of one or more symptoms associated with the disorder; (8) increase in the length of disease-free presentation following treatment; and/or (9) decreased mortality at a given point of time following treatment.

**[0098]** A "lupus therapeutic agent", a "therapeutic agent effective to treat lupus", and grammatical variations thereof, as used herein, refer to an agent that when provided in an effective amount is known, clinically shown, or expected by clinicians to provide a therapeutic benefit in a subject who has lupus. In one embodiment, the phrase includes any agent that is marketed by a manufacturer, or otherwise used by licensed clinicians, as a clinically-accepted agent that when provided in an effective amount would be expected to provide a therapeutic effect in a subject who has lupus. In one embodiment, a lupus therapeutic agent comprises a non-steroidal anti-inflammatory drug (NSAID), which includes acetylsalicylic acid (e.g., aspirin), ibuprofen (Motrin), naproxen (Naprosyn), indomethacin (Indocin), nabumetone (Relafen), tolmetin (Tolectin), and any other embodiments that comprise a therapeutically equivalent active ingredient(s) and formulation thereof. In one embodiment, a lupus therapeutic agent comprises acetaminophen (e.g., Tylenol), corticosteroids, or anti-malarials<sup>3</sup> (e.g., chloroquine, hydroxychloroquine). In one embodiment, a lupus therapeutic agent comprises an immunomodulating drug (e.g., azathioprine, cyclophosphamide, methotrexate, cyclosporine). In one embodiment, a lupus therapeutic agent is an anti-B cell agent (e.g., anti-CD20 (e.g., rituximab), anti-CD22), an anti-cytokine agent (e.g., anti-tumor necrosis factor  $\alpha$ , anti-interleukin-1-receptor (e.g., anakinra), anti-interleukin 10, anti-interleukin 6 receptor, anti-interferon alpha, anti-B-lymphocyte stimulator), an inhibitor of costimulation (e.g., anti-CD154, CTLA4-Ig (e.g.,

abatacept)), a modulator of B-cell anergy (e.g., LJP 394 (e.g., abetimus)). In one embodiment, a lupus therapeutic agent comprises hormonal treatment (e.g., DHEA), and anti-hormonal therapy (e.g., the anti-prolactin agent bromocriptine). In one embodiment, a lupus therapeutic agent is an agent that provides immunoadsorption, is an anti-complement factor (e.g., anti-C5a), T cell vaccination, cell transfection with T-cell receptor zeta chain, or peptide therapies (e.g., edratide targeting anti-DNA idiotypes).

**[0099]** A therapeutic agent that has “marketing approval”, or that has been “approved as a therapeutic agent”, or grammatical variations thereof of these phrases, as used herein, refer to an agent (e.g., in the form of a drug formulation, medicament) that is approved, licensed, registered or authorized by a relevant governmental entity (e.g., federal, state or local regulatory agency, department, bureau) to be sold by and/or through and/or on behalf of a commercial entity (e.g., a for-profit entity) for the treatment of a particular disorder (e.g., lupus) or a patient subpopulation (e.g., patients with lupus nephritis, patients of a particular ethnicity, gender, lifestyle, disease risk profile, etc.). A relevant governmental entity includes, for example, the Food and Drug Administration (FDA), European Medicines Evaluation Agency (EMEA), and equivalents thereof.

**[00100]** “Antibodies” (Abs) and “immunoglobulins” (Igs) refer to glycoproteins having similar structural characteristics. While antibodies exhibit binding specificity to a specific antigen, immunoglobulins include both antibodies and other antibody-like molecules which generally lack antigen specificity. Polypeptides of the latter kind are, for example, produced at low levels by the lymph system and at increased levels by myelomas.

**[00101]** The terms “antibody” and “immunoglobulin” are used interchangeably in the broadest sense and include monoclonal antibodies (e.g., full length or intact monoclonal antibodies), polyclonal antibodies, monovalent antibodies, multivalent antibodies, multispecific antibodies (e.g., bispecific antibodies so long as they exhibit the desired biological activity) and may also include certain antibody fragments (as described in greater detail herein). An antibody can be chimeric, human, humanized and/or affinity matured.

**[0100]** The terms “full length antibody,” “intact antibody” and “whole antibody” are used herein interchangeably to refer to an antibody in its substantially intact form, not antibody fragments as defined below. The terms particularly refer to an antibody with heavy chains that contain the Fc region.

**[0101]** “Antibody fragments” comprise a portion of an intact antibody, preferably comprising the antigen binding region thereof. Examples of antibody fragments include Fab,

Fab', F(ab')<sub>2</sub>, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.

**[0102]** Papain digestion of antibodies produces two identical antigen-binding fragments, called "Fab" fragments, each with a single antigen-binding site, and a residual "Fc" fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab')<sub>2</sub> fragment that has two antigen-combining sites and is still capable of cross-linking antigen.

**[0103]** "Fv" is a minimum antibody fragment which contains a complete antigen-binding site. In one embodiment, a two-chain Fv species consists of a dimer of one heavy- and one light-chain variable domain in tight, non-covalent association. Collectively, the six CDRs of an Fv confer antigen-binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.

**[0104]** The Fab fragment contains the heavy- and light-chain variable domains and also contains the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by the addition of a few residues at the carboxy terminus of the heavy chain CH1 domain including one or more cysteines from the antibody hinge region. Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab')<sub>2</sub> antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.

**[0105]** The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible mutations, e.g., naturally occurring mutations, that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. In certain embodiments, such a monoclonal antibody typically includes an antibody comprising a polypeptide sequence that binds a target, wherein the target-binding polypeptide sequence was obtained by a process that includes the selection of a single target binding polypeptide sequence from a plurality of polypeptide sequences. For example, the selection process can be the selection of a unique clone from a plurality of clones, such as a pool of hybridoma clones, phage clones, or recombinant DNA clones. It should be understood that a selected target binding sequence can be further altered, for example, to improve affinity for the target, to humanize the target binding sequence, to improve its production in cell culture, to reduce

its immunogenicity *in vivo*, to create a multispecific antibody, etc., and that an antibody comprising the altered target binding sequence is also a monoclonal antibody of this invention. In contrast to polyclonal antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. In addition to their specificity, monoclonal antibody preparations are advantageous in that they are typically uncontaminated by other immunoglobulins.

**[0106]** The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including, for example, the hybridoma method (e.g., Kohler et al., *Nature*, 256: 495 (1975); Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2<sup>nd</sup> ed. 1988); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas 563-681 (Elsevier, N.Y., 1981)), recombinant DNA methods (see, e.g., U.S. Patent No. 4,816,567), phage display technologies (see, e.g., Clackson et al., *Nature*, 352: 624-628 (1991); Marks et al., *J. Mol. Biol.* 222: 581-597 (1992); Sidhu et al., *J. Mol. Biol.* 338(2): 299-310 (2004); Lee et al., *J. Mol. Biol.* 340(5): 1073-1093 (2004); Fellouse, *Proc. Natl. Acad. Sci. USA* 101(34): 12467-12472 (2004); and Lee et al., *J. Immunol. Methods* 284(1-2): 119-132(2004), and technologies for producing human or human-like antibodies in animals that have parts or all of the human immunoglobulin loci or genes encoding human immunoglobulin sequences (see, e.g., WO98/24893; WO96/34096; WO96/33735; WO91/10741; Jakobovits et al., *Proc. Natl. Acad. Sci. USA* 90: 2551 (1993); Jakobovits et al., *Nature* 362: 255-258 (1993); Bruggemann et al., *Year in Immunol.* 7:33 (1993); U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016; Marks et al., *Bio. Technology* 10: 779-783 (1992); Lonberg et al., *Nature* 368: 856-859 (1994); Morrison, *Nature* 368: 812-813 (1994); Fishwild et al., *Nature Biotechnol.* 14: 845-851 (1996); Neuberger, *Nature Biotechnol.* 14: 826 (1996) and Lonberg and Huszar, *Intern. Rev. Immunol.* 13: 65-93 (1995).

**[0107]** The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or

homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; and Morrison *et al.*, *Proc. Natl. Acad. Sci. USA* 81:6855-6855 (1984)).

**[0108]** "Humanized" forms of non-human (*e.g.*, murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. In one embodiment, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit, or nonhuman primate having the desired specificity, affinity, and/or capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications may be made to further refine antibody performance. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones *et al.*, *Nature* 321:522-525 (1986); Riechmann *et al.*, *Nature* 332:323-329 (1988); and Presta, *Curr. Op. Struct. Biol.* 2:593-596 (1992). See also the following review articles and references cited therein: Vaswani and Hamilton, *Ann. Allergy, Asthma & Immunol.* 1:105-115 (1998); Harris, *Biochem. Soc. Transactions* 23:1035-1038 (1995); Hurle and Gross, *Curr. Op. Biotech.* 5:428-433 (1994).

**[0109]** A "human antibody" is one which comprises an amino acid sequence corresponding to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies as disclosed herein. Such techniques include screening human-derived combinatorial libraries, such as phage display libraries (see, *e.g.*, Marks *et al.*, *J. Mol. Biol.*, 222: 581-597 (1991) and Hoogenboom *et al.*, *Nucl. Acids Res.*, 19: 4133-4137 (1991)); using human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies (see, *e.g.*, Kozbor *J. Immunol.*, 133: 3001 (1984); Brodeur *et al.*, *Monoclonal Antibody Production Techniques and Applications*, pp. 55-93 (Marcel Dekker, Inc., New York, 1987); and Boerner *et al.*, *J. Immunol.*, 147: 86

(1991)); and generating monoclonal antibodies in transgenic animals (e.g., mice) that are capable of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production (see, e.g., Jakobovits *et al.*, *Proc. Natl. Acad. Sci USA*, 90: 2551 (1993); Jakobovits *et al.*, *Nature*, 362: 255 (1993); Brugermann *et al.*, *Year in Immunol.*, 7: 33 (1993)). This definition of a human antibody specifically excludes a humanized antibody comprising antigen-binding residues from a non-human animal.

**[0110]** An “affinity matured” antibody is one with one or more alterations in one or more CDRs thereof which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess those alteration(s). In one embodiment, an affinity matured antibody has nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies are produced by procedures known in the art. Marks *et al.* *Bio/Technology* 10:779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of HVR and/or framework residues is described by: Barbas *et al.* *Proc Nat. Acad. Sci. USA* 91:3809-3813 (1994); Schier *et al.* *Gene* 169:147-155 (1995); Yelton *et al.* *J. Immunol.* 155:1994-2004 (1995); Jackson *et al.*, *J. Immunol.* 154(7):3310-9 (1995); and Hawkins *et al.*, *J. Mol. Biol.* 226:889-896 (1992).

**[0111]** A “blocking antibody” or an “antagonist antibody” is one which inhibits or reduces a biological activity of the antigen it binds. Certain blocking antibodies or antagonist antibodies partially or completely inhibit the biological activity of the antigen.

**[0112]** A “small molecule” or “small organic molecule” is defined herein as an organic molecule having a molecular weight below about 500 Daltons.

**[0113]** The word "label" when used herein refers to a detectable compound or composition. The label may be detectable by itself (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which results in a detectable product. Radionuclides that can serve as detectable labels include, for example, I-131, I-123, I-125, Y-90, Re-188, Re-186, At-211, Cu-67, Bi-212, and Pd-109.

**[0114]** An "isolated" biological molecule, such as a nucleic acid, polypeptide, or antibody, is one which has been identified and separated and/or recovered from at least one component of its natural environment.

**[0115]** Reference to “about” a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. For example, description referring to “about X” includes description of “X.”

## GENERAL TECHNIQUES

**[0116]** Nucleotide variations associated with lupus are provided herein. These variations provide biomarkers for lupus, and/or predispose or contribute to development, persistence and/or progression of lupus. Accordingly, the invention disclosed herein is useful in a variety of settings, e.g., in methods and compositions related to lupus diagnosis and therapy.

**[0117]** In certain embodiments, the methods relate to prognosis, i.e., the prediction of the likelihood of autoimmune disorder-attributable disease symptoms, including, for example, recurrence, flaring, and drug resistance, of an autoimmune disease such as lupus. In one embodiment, the prediction relates to the extent of those responses. In one embodiment, the prediction relates to whether and/or the probability that a patient will survive or improve following treatment, for example treatment with a particular therapeutic agent, and for a certain period of time without disease recurrence. The predictive methods of the invention can be used clinically to make treatment decisions by choosing the most appropriate treatment modalities for any particular patient. The predictive methods of the present invention are valuable tools in predicting if a patient is likely to respond favorably to a treatment regimen, such as a given therapeutic regimen, including for example, administration of a given therapeutic agent or combination, surgical intervention, steroid treatment, etc., or whether long-term survival of the patient, following a therapeutic regimen is likely. Diagnosis of SLE may be according to current American College of Rheumatology (ACR) criteria. Active disease may be defined by one British Isles Lupus Activity Group's (BILAG) "A" criteria or two BILAG "B" criteria. Some signs, symptoms, or other indicators used to diagnose SLE adapted from: Tan *et al.* "The Revised Criteria for the Classification of SLE" *Arth Rheum* 25 (1982) may be malar rash such as rash over the cheeks, discoid rash, or red raised patches, photosensitivity such as reaction to sunlight, resulting in the development of or increase in skin rash, oral ulcers such as ulcers in the nose or mouth, usually painless, arthritis, such as non-erosive arthritis involving two or more peripheral joints (arthritis in which the bones around the joints do not become destroyed), serositis, pleuritis or pericarditis, renal disorder such as excessive protein in the urine (greater than 0.5 gm/day or 3+ on test sticks) and/or cellular casts (abnormal elements derived from the urine and/or white cells and/or kidney tubule cells), neurologic signs, symptoms, or other indicators, seizures (convulsions), and/or psychosis in the absence of drugs or metabolic disturbances that are known to cause such effects, and hematologic signs, symptoms, or other indicators such as hemolytic anemia or leukopenia (white bloodcount below 4,000 cells per cubic millimeter) or lymphopenia (less

than 1,500 lymphocytes per cubic millimeter) or thrombocytopenia (less than 100,000 platelets per cubic millimeter). The leukopenia and lymphopenia generally must be detected on two or more occasions. The thrombocytopenia generally must be detected in the absence of drugs known to induce it. The invention is not limited to these signs, symptoms, or other indicators of lupus.

#### Detection of Genetic Variations

**[0118]** Nucleic acid, according to any of the above methods, may be genomic DNA; RNA transcribed from genomic DNA; or cDNA generated from RNA. Nucleic acid may be derived from a vertebrate, e.g., a mammal. A nucleic acid is said to be “derived from” a particular source if it is obtained directly from that source or if it is a copy of a nucleic acid found in that source.

**[0119]** Nucleic acid includes copies of the nucleic acid, e.g., copies that result from amplification. Amplification may be desirable in certain instances, e.g., in order to obtain a desired amount of material for detecting variations. The amplicons may then be subjected to a variation detection method, such as those described below, to determine whether a variation is present in the amplicon.

**[0120]** Variations may be detected by certain methods known to those skilled in the art. Such methods include, but are not limited to, DNA sequencing; primer extension assays, including allele-specific nucleotide incorporation assays and allele-specific primer extension assays (e.g., allele-specific PCR, allele-specific ligation chain reaction (LCR), and gap-LCR); allele-specific oligonucleotide hybridization assays (e.g., oligonucleotide ligation assays); cleavage protection assays in which protection from cleavage agents is used to detect mismatched bases in nucleic acid duplexes; analysis of MutS protein binding; electrophoretic analysis comparing the mobility of variant and wild type nucleic acid molecules; denaturing-gradient gel electrophoresis (DGGE, as in, e.g., Myers et al. (1985) *Nature* 313:495); analysis of RNase cleavage at mismatched base pairs; analysis of chemical or enzymatic cleavage of heteroduplex DNA; mass spectrometry (e.g., MALDI-TOF); genetic bit analysis (GBA); 5' nuclease assays (e.g., TaqMan<sup>®</sup>); and assays employing molecular beacons. Certain of these methods are discussed in further detail below.

**[0121]** Detection of variations in target nucleic acids may be accomplished by molecular cloning and sequencing of the target nucleic acids using techniques well known in the art. Alternatively, amplification techniques such as the polymerase chain reaction (PCR) can be used to amplify target nucleic acid sequences directly from a genomic DNA preparation from

tumor tissue. The nucleic acid sequence of the amplified sequences can then be determined and variations identified therefrom. Amplification techniques are well known in the art, e.g., polymerase chain reaction is described in Saiki et al., *Science* 239:487, 1988; U.S. Pat. Nos. 4,683,203 and 4,683,195.

**[0122]** The ligase chain reaction, which is known in the art, can also be used to amplify target nucleic acid sequences. See, e.g., Wu et al., *Genomics* 4:560-569 (1989). In addition, a technique known as allele-specific PCR can also be used to detect variations (e.g., substitutions). See, e.g., Ruano and Kidd (1989) *Nucleic Acids Research* 17:8392; McClay et al. (2002) *Analytical Biochem.* 301:200-206. In certain embodiments of this technique, an allele-specific primer is used wherein the 3' terminal nucleotide of the primer is complementary to (i.e., capable of specifically base-pairing with) a particular variation in the target nucleic acid. If the particular variation is not present, an amplification product is not observed. Amplification Refractory Mutation System (ARMS) can also be used to detect variations (e.g., substitutions). ARMS is described, e.g., in European Patent Application Publication No. 0332435, and in Newton et al., *Nucleic Acids Research*, 17:7, 1989.

**[0123]** Other methods useful for detecting variations (e.g., substitutions) include, but are not limited to, (1) allele-specific nucleotide incorporation assays, such as single base extension assays (see, e.g., Chen et al. (2000) *Genome Res.* 10:549-557; Fan et al. (2000) *Genome Res.* 10:853-860; Pastinen et al. (1997) *Genome Res.* 7:606-614; and Ye et al. (2001) *Hum. Mut.* 17:305-316); (2) allele-specific primer extension assays (see, e.g., Ye et al. (2001) *Hum. Mut.* 17:305-316; and Shen et al. *Genetic Engineering News*, vol. 23, Mar. 15, 2003), including allele-specific PCR; (3) 5' nuclease assays (see, e.g., De La Vega et al. (2002) *BioTechniques* 32:S48-S54 (describing the TaqMan® assay); Ranade et al. (2001) *Genome Res.* 11:1262-1268; and Shi (2001) *Clin. Chem.* 47:164-172); (4) assays employing molecular beacons (see, e.g., Tyagi et al. (1998) *Nature Biotech.* 16:49-53; and Mhlanga et al. (2001) *Methods* 25:463-71); and (5) oligonucleotide ligation assays (see, e.g., Grossman et al. (1994) *Nuc. Acids Res.* 22:4527-4534; patent application Publication No. US 2003/0119004 A1; PCT International Publication No. WO 01/92579 A2; and U.S. Pat. No. 6,027,889).

**[0124]** Variations may also be detected by mismatch detection methods. Mismatches are hybridized nucleic acid duplexes which are not 100% complementary. The lack of total complementarity may be due to deletions, insertions, inversions, or substitutions. One example of a mismatch detection method is the Mismatch Repair Detection (MRD) assay described, e.g., in Faham et al., *Proc. Natl Acad. Sci. USA* 102:14717-14722 (2005) and

Faham et al., *Hum. Mol. Genet.* 10:1657-1664 (2001). Another example of a mismatch cleavage technique is the RNase protection method, which is described in detail in Winter et al., *Proc. Natl. Acad. Sci. USA*, 82:7575, 1985, and Myers et al., *Science* 230:1242, 1985. For example, a method of the invention may involve the use of a labeled riboprobe which is complementary to the human wild-type target nucleic acid. The riboprobe and target nucleic acid derived from the tissue sample are annealed (hybridized) together and subsequently digested with the enzyme RNase A which is able to detect some mismatches in a duplex RNA structure. If a mismatch is detected by RNase A, it cleaves at the site of the mismatch. Thus, when the annealed RNA preparation is separated on an electrophoretic gel matrix, if a mismatch has been detected and cleaved by RNase A, an RNA product will be seen which is smaller than the full-length duplex RNA for the riboprobe and the mRNA or DNA. The riboprobe need not be the full length of the target nucleic acid, but can a portion of the target nucleic acid, provided it encompasses the position suspected of having a variation.

**[0125]** In a similar manner, DNA probes can be used to detect mismatches, for example through enzymatic or chemical cleavage. See, e.g., Cotton et al., *Proc. Natl. Acad. Sci. USA*, 85:4397, 1988; and Shenk et al., *Proc. Natl. Acad. Sci. USA*, 72:989, 1975. Alternatively, mismatches can be detected by shifts in the electrophoretic mobility of mismatched duplexes relative to matched duplexes. See, e.g., Cariello, *Human Genetics*, 42:726, 1988. With either riboprobes or DNA probes, the target nucleic acid suspected of comprising a variation may be amplified before hybridization. Changes in target nucleic acid can also be detected using Southern hybridization, especially if the changes are gross rearrangements, such as deletions and insertions.

**[0126]** Restriction fragment length polymorphism (RFLP) probes for the target nucleic acid or surrounding marker genes can be used to detect variations, e.g., insertions or deletions. Insertions and deletions can also be detected by cloning, sequencing and amplification of a target nucleic acid. Single stranded conformation polymorphism (SSCP) analysis can also be used to detect base change variants of an allele. See, e.g. Orita et al., *Proc. Natl. Acad. Sci. USA* 86:2766-2770, 1989, and *Genomics*, 5:874-879, 1989.

**[0127]** A microarray is a multiplex technology that typically uses an arrayed series of thousands of nucleic acid probes to hybridize with, e.g., a cDNA or cRNA sample under high-stringency conditions. Probe-target hybridization is typically detected and quantified by detection of fluorophore-, silver-, or chemiluminescence-labeled targets to determine relative abundance of nucleic acid sequences in the target. In typical microarrays, the probes are

attached to a solid surface by a covalent bond to a chemical matrix (via epoxy-silane, amino-silane, lysine, polyacrylamide or others). The solid surface is for example, glass, a silicon chip, or microscopic beads. Various microarrays are commercially available, including those manufactured, for example, by Affymetrix, Inc. and Illumina, Inc.

**[0128]** A biological sample may be obtained using certain methods known to those skilled in the art. Biological samples may be obtained from vertebrate animals, and in particular, mammals. Tissue biopsy is often used to obtain a representative piece of tumor tissue. Alternatively, tumor cells can be obtained indirectly in the form of tissues or fluids that are known or thought to contain the tumor cells of interest. For instance, samples of lung cancer lesions may be obtained by resection, bronchoscopy, fine needle aspiration, bronchial brushings, or from sputum, pleural fluid or blood. Variations in target nucleic acids (or encoded polypeptides) may be detected from a tumor sample or from other body samples such as urine, sputum or serum. (Cancer cells are sloughed off from tumors and appear in such body samples.) By screening such body samples, a simple early diagnosis can be achieved for diseases such as cancer. In addition, the progress of therapy can be monitored more easily by testing such body samples for variations in target nucleic acids (or encoded polypeptides). Additionally, methods for enriching a tissue preparation for tumor cells are known in the art. For example, the tissue may be isolated from paraffin or cryostat sections. Cancer cells may also be separated from normal cells by flow cytometry or laser capture microdissection.

**[0129]** Subsequent to the determination that a subject, or the tissue or cell sample comprises a genetic variation disclosed herein, it is contemplated that an effective amount of an appropriate lupus therapeutic agent may be administered to the subject to treat the lupus condition in the subject. Diagnosis in mammals of the various pathological conditions described herein can be made by the skilled practitioner. Diagnostic techniques are available in the art which allow, e.g., for the diagnosis or detection of lupus in a mammal.

**[0130]** A lupus therapeutic agent can be administered in accordance with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Optionally, administration may be performed through mini-pump infusion using various commercially available devices.

**[0131]** Effective dosages and schedules for administering lupus therapeutic agents may be determined empirically, and making such determinations is within the skill in the art. Single or multiple dosages may be employed. For example, an effective dosage or amount of interferon

inhibitor used alone may range from about 1 mg/kg to about 100 mg/kg of body weight or more per day. Interspecies scaling of dosages can be performed in a manner known in the art, e.g., as disclosed in Mordini et al., *Pharmaceut. Res.*, 8:1351 (1991).

**[0132]** When *in vivo* administration of a lupus therapeutic agent is employed, normal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1  $\mu$ g/kg/day to 10 mg/kg/day, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue, for example, may necessitate delivery in a manner different from that to another organ or tissue.

**[0133]** It is contemplated that yet additional therapies may be employed in the methods. The one or more other therapies may include but are not limited to, administration of steroids and other standard of care regimens for the disorder in question. It is contemplated that such other therapies may be employed as an agent separate from, e.g., a targeted lupus therapeutic agent.

#### Kits

**[0134]** For use in the applications described or suggested above, kits or articles of manufacture are also provided. Such kits may comprise a carrier means being compartmentalized to receive in close confinement one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method. For example, one of the container means may comprise a probe that is or can be detectably labeled. Such probe may be a polynucleotide specific for a polynucleotide comprising a SLE risk locus. Where the kit utilizes nucleic acid hybridization to detect the target nucleic acid, the kit may also have containers containing nucleotide(s) for amplification of the target nucleic acid sequence and/or a container comprising a reporter means, such as a biotin-binding protein, such as avidin or streptavidin, bound to a reporter molecule, such as an enzymatic, fluorescent, or radioisotope label.

**[0135]** Kits will typically comprise the container described above and one or more other containers comprising materials desirable from a commercial and user standpoint, including buffers, diluents, filters, needles, syringes, and package inserts with instructions for use. A label may be present on the container to indicate that the composition is used for a specific therapy or

non-therapeutic application, and may also indicate directions for either *in vivo* or *in vitro* use, such as those described above.

**[0136]** Other optional components in the kit include one or more buffers (*e.g.*, block buffer, wash buffer, substrate buffer, etc), other reagents such as substrate (*e.g.*, chromogen) which is chemically altered by an enzymatic label, epitope retrieval solution, control samples (positive and/or negative controls), control slide(s) etc. An additional component is an enzyme, for example, including but not limited to, a nuclease, a ligase, or a polymerase.

**Methods of Marketing**

**[0137]** Also provided are methods for marketing a lupus therapeutic agent or a pharmaceutically acceptable composition thereof comprising promoting to, instructing, and/or specifying to a target audience, the use of the agent or pharmaceutical composition thereof for treating a patient or patient population with lupus from which a sample has been obtained showing the presence of a genetic variation as disclosed herein.

**[0138]** Marketing is generally paid communication through a non-personal medium in which the sponsor is identified and the message is controlled. Marketing for purposes herein includes publicity, public relations, product placement, sponsorship, underwriting, and sales promotion. This term also includes sponsored informational public notices appearing in any of the print communications media designed to appeal to a mass audience to persuade, inform, promote, motivate, or otherwise modify behavior toward a favorable pattern of purchasing, supporting, or approving the invention herein.

**[0139]** The marketing of diagnostic methods may be accomplished by any means. Examples of marketing media used to deliver these messages include television, radio, movies, magazines, newspapers, the internet, and billboards, including commercials, which are messages appearing in the broadcast media.

**[0140]** The type of marketing used will depend on many factors, for example, on the nature of the target audience to be reached, *e.g.*, hospitals, insurance companies, clinics, doctors, nurses, and patients, as well as cost considerations and the relevant jurisdictional laws and regulations governing marketing of medicaments and diagnostics. The marketing may be individualized or customized based on user characterizations defined by service interaction and/or other data such as user demographics and geographical location.

**[0141]** The following are examples of the methods and compositions of the invention. It is understood that various other embodiments may be practiced, given the general description provided above.

## EXAMPLES

**[0142]** Throughout the Examples, references to certain publications are denoted by numbers, which have complete bibliography information at the end of the Examples section.

### **Example 1**

#### **Identification of Novel Risk Loci for SLE**

##### **Methods and Subjects**

##### **Subjects**

**[0143]** The selection and genotyping of SLE cases, the samples used in the genome-wide association scan (GWAS) as well as controls from the New York Health Project (NYHP) collection (Mitchell et al., *J Urban Health* 81(2):301-10 (2004)), were described previously (Hom et al., *N Engl J Med* 358(9):900-9 (2008)). As detailed below, the SLE cases consisted of three case series: a) 338 cases from the Autoimmune Biomarkers Collaborative Network (ABCOn) (Bauer et al., *PLoS medicine* 3(12):e491 (2006)), an NIH/NIAMS-funded repository, and 141 cases from the Multiple Autoimmune Disease Genetics Consortium (MADGC) (Criswell et al., *Am J Hum Genet* 76(4):561-71 (2005)); b) 613 cases from the University of California San Francisco (UCSF) Lupus Genetics Project (Seligman et al., *Arthritis Rheum* 44(3):618-25 (2001); Remmers et al., *N Engl J Med* 357(10):977-86 (2007)); and c) 335 cases from the University of Pittsburgh Medical Center (UPMC) (Demirci et al., *Ann Hum Genet* 71(Pt 3):308-11 (2007)) and 8 cases from The Feinstein Institute for Medical Research. The controls were 1861 samples from the NYHP collection, 1722 samples from the publicly available iControlDB database (available at Illumina Inc.), and 4564 samples from the publicly available National Cancer Institute Cancer Genetic Markers of Susceptibility (CGEMS) project (available at the URL: [cgems\(dot\)cancer\(dot\)gov](http://cgems(dot)cancer(dot)gov)).

#### **GENOMEWIDE DATA SET OF 1310 SLE CASES AND 7859 CONTROLS**

**[0144]** We previously described the selection and genotyping of SLE case samples (Hom et al., *N Engl J Med* 358(9):900-9 (2008)). All SLE cases were North Americans of European descent, as determined by self-report and confirmed by genotyping. The diagnosis of SLE (fulfillment of four or more of the American College of Rheumatology [ACR] defined criteria [Hochberg et al., *Arthritis Rheum* 40(9):1725[1997]]) was confirmed in all cases by medical record review (94%) or through written documentation of criteria by treating rheumatologists (6%). Clinical data for these case series are presented elsewhere (Seligman et al., *Arthritis Rheum* 44(3):618-25 (2001); Criswell et al., *Am J Hum Genet* 76(4):561-71 (2005); Bauer et

al., PLoS medicine 3(12):e491 (2006); Demirci et al., Ann Hum Genet 71(Pt 3):308-11 (2007); Remmers et al., N Engl J Med 357(10):977-86 (2007)). Genotyping and selection of the NYHP samples was described previously (Hom et al., N Engl J Med 358(9):900-9 (2008)). Table 1 describes the number of samples contributed organized by site.

**[0145]** Sample and SNP filtering was conducted using analytical modules within the software programs PLINK and EIGENSTRAT as described below (*see also* Purcell et al., Am J Hum Genet 81(3):559-75 (2007); Price et al., Nat Genet 38(8):904-09 (2006)). The genomewide SNP data were used in this study to facilitate close matching of cases and controls, and to provide genotypes at the confirmed and suspected SLE loci.

**Table 1. Number of samples analyzed in genome-wide and replication study organized by site.**

	Case Collection	N	Control Collection	N
<b>Discovery samples</b>				
GWAS <sup>a</sup>		1310		7859
<b>Replication samples</b>				
US <sup>b</sup>	PROFILE	415	NYHP	776
	UMN	366	ALZ	2215
	UCSF	284		
	UPMC	52		
	JHU	12		
	Total	1129		2991
Sweden <sup>c</sup>	Umeå	244	Umeå	-
	Uppsala	145	Uppsala	132
	Stockholm	270	Stockholm <sup>d</sup>	1112
	Lund	155	Lund	94
	Total	834	Total	1338
<b>Total</b>		<b>3273</b>		<b>12188</b>

<sup>a</sup> Samples from the genome-wide association scan described (Hom, G. et al., *N Engl J Med* 358:900-9 (2008)). <sup>b</sup> Independent SLE cases from a U.S. cohort drawn from the PROFILE SLE consortium, University of California- San Francisco (UCSF) (Thorburn, C.M. et al., *Genes Immun* 8:279-87 (2007)), University of Pittsburgh Medical Center (UPMC), University of Minnesota (UMN), and Johns Hopkins University (JHU). U.S. controls from the New York Health Project (Gregersen et al.) and Alzhiemers cases and controls from the University of Pittsburgh and the NCRAD. <sup>c</sup> SLE cases and controls from Stockholm, Karolinska, Solna, Uppsala, Lund and Umeå, Sweden. <sup>d</sup> 823 of the controls from Stockholm were genotyped using the Illumina 317K SNP array. SNPs in these samples were imputed and analyzed as described in Methods.

#### Custom SNP Array

**[0146]** A custom array was designed with 10,848 SNPs that passed the quality control measures described below. The complete array had 12,864 SNPs but 2016 SNPs failed the quality control measures leaving 10,848 SNPs that were advanced into the analysis. The custom array consisted of 3,188 SNPs selected based on a nominal  $P < 0.05$  in a SLE genome-wide association scan, 505 SNPs from 25 previously reported SLE risk loci, 42 SNPs selected after a literature search for confirmed risk alleles from other autoimmune diseases and 7,113 SNPs used for ascertaining and controlling for population substructure. The latter group included SNPs that have been used to define continental population differences (Kosoy, R. et al., *Hum. Mutat.* 30:69-78 (2009)) and SNPs enriched for European population substructure (Tian, C. et al., *PLoS Genet* 4, e4 (2008)). The custom array was manufactured

by Illumina, Inc. using their iSelect Custom BeadChip and the rs identification numbers we provided for the SNPs that passed the quality control filters described below.

### Quality Control and Imputation

**[0147]** For the U.S. data, a total of 1,464 U.S. cases and 3,078 U.S. controls were genotyped on the custom Illumina chip described above, also referred to herein as the custom 12K chip. We used stringent quality control (QC) criteria to ensure that high quality data was included in the final analysis. Specifically, we a) excluded 116 individuals who had > 5% missing data and b) excluded 279 individuals based on cryptic relatedness and duplicate samples based on Identical by State (IBS) status ( $\text{PI Hat} > 0.15$ ). We included only SNPs with a) < 5 % missing data, b) Hardy-Weinberg Equilibrium (HWE) p-value  $> 1 \times 10^{-6}$ , c) Minor Allele Frequency (MAF)  $> 0.01 \%$  and d) SNPs with p-value  $> 1 \times 10^{-5}$  in a test for differential missingness between cases and controls. SNPs were also examined for batch effects. After applying the above filters, a final set of 1,144 cases and 3,003 controls and 11,024 SNPs were available for analysis. All QC tests were performed using PLINK (Purcell et al., Am J Hum Genet 81(3):559-75 (2007)).

**[0148]** For the Swedish data, a set of 888 cases and 527 controls genotyped on the custom 12K chip were available for analysis. A separate set of 1,115 Swedish controls genotyped on the Illumina, Inc. 317K Human HapMap SNP bead array (also referred to herein as the 317K array) was also incorporated into the analysis. We followed the following steps to combine the two data sets. First, an overlapping data set of 6,789 SNPs between the 12K and 317K data was created. We used this data set to examine the Swedish replication cohort for cryptic relatedness and duplicate samples. As a result, 313 samples were excluded ( $\text{PI Hat} > 0.15$ ). After quality control checks, we forwarded for analysis 863 cases and 523 controls genotyped on the custom 12K chip and 831 controls genotyped on the 317K Illumina chip. Second, we imputed (see below) the 831 Swedish controls genotyped with the 317K array to create a larger set of overlapping SNPs. Of the remaining SNPs, we captured 4,605 SNPs by imputation. A final set of 11,394 overlapping SNPs was forwarded to analysis. We filtered the SNPs in this data set using the same thresholds as described above. The remaining 1,250 SNPs not captured by the imputation were analyzed only in the original set of Swedish samples genotyped on the 12K chip.

**[0149]** The 831 Swedish controls genotyped with the 317K array were imputed using MACH (a Markov Chain based haplotyping software program available at the URL [sph.umich.edu/csg/abecasis/MACH](http://sph.umich.edu/csg/abecasis/MACH)) using Phase II HapMap CEU

samples as a reference. Phase II HapMap CEU refers to samples from the Human Haplotype Project known as Utah residents with ancestry from northern and western Europe (CEU) from the “Phase II” data release. (See also Li et al. *Am J Hum Genet* **S79** at 2290 (2006)). Before imputation, we applied stringent quality control checks on the 317K SNPs. A subset of 293,242 markers passing the following criteria (1) MAF > 1%, (2) missing rate < 5% and (3) HWE p-value  $>1\times10^{-6}$  were included in the imputation. After the imputation, SNPs with low imputation quality, i.e. R-squared\_Hat (RSQR\_HAT) < 0.40 reported by MACH, were discarded. An overlapping set of 11,394 markers was available for analysis. To take into account the uncertainty in imputation, probabilistic scores rather than genotype calls were used in the analysis.

**[0150]** For imputation of genome-wide association study samples, genotype data used in the meta-analysis was from 1310 SLE cases genotyped with the Illumina 550K genome-wide SNP platform (see Hom, G. et al., *N Engl J Med* 358:900-9 (2008)). The selection and genotyping of the SLE case samples was described previously (Hom, G. et al., *N Engl J Med* 358:900-9 (2008)). In addition to the 3,583 controls previously described (Hom, G. et al., *N Engl J Med* 358:900-9 (2008)), 4,564 control samples from the publicly available Cancer Genetics Markers of Susceptibility (CGEMS) project were included after obtaining approval (available at the URL: cgems(dot)cancer(dot)gov). The entire sample of 7,859 controls was examined using the data quality control filters as previously described (Hom, G. et al., *N Engl J Med* 358:900-9 (2008)). We next used IMPUTE version 1 (available at the URL [www.stats.ox.ac.uk/~marchini/software/slash/gwas/slash/impute.html](http://www.stats.ox.ac.uk/~marchini/software/slash/gwas/slash/impute.html)) to infer genotypes using HapMap Phase II CEU samples as a reference (Marchini, J. et al., *Nat. Genet.* 39:906-913 (2007)). We used SNPTEST (available at the URL [www.stats.ox.ac.uk/~marchini/software/slash/gwas/slash/snptest\\_v1.1.4.html](http://www.stats.ox.ac.uk/~marchini/software/slash/gwas/slash/snptest_v1.1.4.html)) to generate association statistics (Marchini, J. et al., *Nat. Genet.* 39:906-913 (2007)). Specifically, association statistics were generated using an additive model (-Frequentist 1 option in SNPTEST), adjusted for the uncertainty of the imputed genotype (-proper option in SNPTEST). The rank ordered list of association statistics was used to select regions for replication as described.

#### **Population Stratification in Replication Samples**

**[0151]** For each replication cohort, we used ancestry informative markers to correct for possible population stratification. A subset of 5,486 uncorrelated ancestry informative

markers that passed stringent quality control criteria were used to infer the top ten principal components of genetic variation using the software EIGENSTRAT (Price et al., *Nat Genet* 38(8):904-09 (2006)). Outliers were removed from each sample set (defined as  $\sigma > 6$ ). Specifically, we removed 27 genetic outliers from the US cohort and 45 outliers from the Swedish cohort respectively. Some degree of population stratification along the first two eigenvectors was observed in both the US and Swedish replication collections. To correct for the case-control stratification, we used one of the following strategies: (1) we applied the correction of the Cochran-Armitage test statistic incorporated in EIGENSTRAT to the US replication data set and to Swedish data set wherever genotype data was available; (2) we used principal components as covariates in a logistic regression model in the analysis of the imputed Swedish data.

### Association Analysis

[0152] For the U.S. data, some inflation in the test statistics was observed after performing an uncorrected 1-degree of freedom allelic test for association (PLINK [Purcell, S. et al. *Am J Hum Genet* 81:559-75 (2007)]). To correct for population stratification in the U.S. sample, principal component analysis (EIGENSTRAT) using 5,486 uncorrelated ancestry informative markers was conducted. First, we removed genetic outliers (defined as  $\sigma > 6$ ). Second, Cochran-Armitage trend chi-square test statistics were calculated for each genotyped SNP in 1,129 cases and 2,991 controls, followed by adjustment of the test statistic value of each SNP in EIGENSTRAT using the first four eigenvectors. Two-tailed p-values based on the test-statistic for each SNP was calculated. After correction for population stratification, the  $\lambda_{gc}$  in the U.S. samples was 1.05.

[0153] For the Swedish data, we examined the Swedish cohort for hidden population stratification using 5,486 ancestry informative markers genotyped in the 12K samples as well as in additional Illumina 317K controls. After removal of genetic outliers, we had 834 cases and 515 controls genotyped on the custom 12K chip and 823 controls genotyped on the Illumina 317K chip. We used the correction of the test statistic implemented in EIGENSTRAT on the overlapping set of 6789 SNPs between the two Illumina arrays. To correct for stratification in the set of 4605 SNPs genotyped in the 12K samples and imputed in the Illumina 317K samples, we used the first four eigenvectors determined above as covariates in a logistic regression model implemented in SNPTTEST because EIGENSTRAT was not intended for use with imputed genotype data. A small set of 1250 markers not captured by imputation in the Illumina 317K SNPs was analyzed only in the 834 cases and

515 controls genotyped on the custom 12K chip. After correction for population stratification the  $\lambda_{gc}$  in the Swedish samples was 1.10.

### Meta-Analysis

**[0154]** We used a weighted z-score method to conduct the meta-analysis. To combine results across different cohorts, alleles were oriented to the forward strand of the National Center for Biotechnology Information (NCBI) 36 reference sequence of the human genome to avoid ambiguity associated with C/G and A/T SNPs. The NCBI reference sequence of the human genome is available at the URL [www\(dot\)ncbi\(dot\)nlm\(dot\)nih\(dot\)gov](http://www.ncbi.nlm.nih.gov). *See also* Pruitt et al., Nucl. Acids Res. 35 (database issue):D61-D65 (2007). P values for each cohort were converted to z-scores taking into account direction of effect relative to an arbitrary reference allele. A weighted sum of z-scores was calculated by weighing each z-score by the square root of the sample size for each cohort and then dividing the sum by the square root of the total sample size. The combined z-score for the Swedish and U.S. replication cohorts were converted to one-tailed p values. The meta-analysis z-score was converted to a two-tailed p value and evidence for association was evaluated. We considered SNPs passing a threshold of  $5 \times 10^{-8}$  overwhelmingly associated with SLE. Loci with combined p-value less than  $1 \times 10^{-5}$  that did not pass genome-wide significance were considered strong candidates. The meta-analysis method was carried out using the freely available METAL software package (available at the URL

[www\(dot\)sph\(dot\)umich\(dot\)edu\(slash\)csg\(slash\)abecasis\(slash\)Metal](http://www.sph.umich.edu/CGSG/abecasis/Metal)). To calculate pooled odds ratios, we used the Cochran-Mantel-Haenszel (CMH) method as implemented by the METAL software. Odds ratios were calculated relative to the risk allele for each SNP. Also, a weighted average allele frequency in controls was calculated relative to the risk allele of each SNP.

### Percent Variance Explained

**[0155]** For SNPs previously associated with SLE and SNPs with a meta p-value less than  $1 \times 10^{-5}$  in our replication study, we calculated the percentage of variance explained. We used a liability threshold model which assumes that SLE has an underlying liability score which is normally distributed with mean 0 and variance one. We assumed prevalence of 0.1% of SLE in the general population. To calculate threshold for each genotype, we used allele frequencies in controls and an effect size corresponding to the odds ratio (OR) from our analysis.

### Interaction Analysis

[0156] To look for epistatic effects between the top signals, we compiled a list of all SNPs in Tables 2, 4, and 6 and carried out an interaction analysis in each replication cohort using the epistasis option implemented in PLINK. To achieve greater statistical power, we performed a case-only analysis. After correcting for the number of tests, none of the SNP-SNP interactions were found significant at the  $p < 0.05$  level.

### Conditional Analysis

[0157] In each genomic region showing strong association with SLE, we selected the SNP showing the strongest signal. We used PLINK to condition on this SNP and looked for other SNPs showing strong association with SLE.

### **A Large-Scale Replication Study Identifies *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10* as Novel Risk Loci for Systemic Lupus Erythematosus**

[0158] Recent genome-wide association (GWA) and candidate gene studies have identified at least 15 common risk alleles that achieve genome-wide significance ( $P < 5 \times 10^{-8}$ ). These include genes important for adaptive immunity and the production of autoantibodies (HLA class II alleles, *BLK*, *PTPN22*, and *BANK1*) and genes with roles in innate immunity and interferon signaling (*ITGAM*, *TNFAIP3*, *STAT4*, and *IRF5*) (Cunningham Graham, D.S. et al., *Nat. Genet.* 40:83-89 (2008); Graham, R.R. et al., *Nat. Genet.* 40(9):1059-61 (2008); Graham, R.R., et al., *J Intern Med* 265:680-88 (2009); Harley, J.B. et al., *Nat. Genet.* 40:204-10 (2008); Hom, G. et al., *N Engl J Med* 358:900-9 (2008); Kozyrev, S.V. et al., *Nat. Genet.* 40:211-6 (2008); Sawalha, A.H. et al., *PLoS ONE* 3:e1727 (2008); Sigurdsson, S. et al., *Am J Hum Genet* 76:528-37 (2005)). To identify additional risk loci we performed a targeted replication study of SNPs from 2,466 loci that showed a nominal  $P$  value  $< 0.05$  in a recent GWAS7 scan of 1310 cases and 7859 controls. We also genotyped SNPs from 25 previously reported SLE risk loci, 42 SNPs from 35 loci implicated in other autoimmune diseases, and over 7,000 ancestry informative markers. An overview of the experimental design is shown in Figure 1. The SNPs described above were incorporated into an Illumina custom SNP array. The array was genotyped in independent cases and controls from the U.S. and Sweden. Eight hundred twenty-three of the Swedish controls were genotyped using the Illumina 310K SNP array and variants were analyzed as described in the Methods above.

[0159] Specifically, as described above, we designed a custom SNP array consisting of  $> 12,000$  variants and genotyped two independent SLE case and control populations from the

United States (1,129 SLE cases and 2,991 controls) and Sweden (834 SLE cases and 1,338 controls). Included among the U.S. controls were 2,215 Alzheimer's disease case/control samples, which were felt to be acceptable as controls since the genetic basis of SLE and Alzheimer's are expected to be independent. We next applied data quality filters to remove poor performing samples and SNPs, population outliers and duplicate/related individuals (see Methods above). Following these quality control measures, a final set of 10,848 SNPs was examined as indicated in Figure 1. Association statistics for 3,735 variants were calculated and corrected for population stratification using 7,113 ancestry informative markers (see Methods above).

**[0160]** We first examined 25 variants (from 23 loci) that were previously reported to be associated with SLE (see Table 2). We found further evidence of association for 21 of the variants ( $P < 0.05$ ), including 9 loci that reached genome-wide significance ( $P < 5 \times 10^{-8}$ ) in the current combined data set. Among the genome-wide significant results were HLA Class II *DR3* (*DRB1\*0301*), *IRF5*, *TNFAIP3*, *BLK*, *STAT4*, *ITGAM*, *PTPN22*, *PHRF1* (*KIAA1542*), and *TNFSF4* (*OX40L*). The analysis provided additional evidence for variants from 9 loci where a single previous study reported genome-wide levels of significance: HLA \*DR2, *TNFAIP3* (rs6920220), *BANK1*, *ATG5*, *PTTG1*, *PXK*, *FCGR2A*, *UBE2L3*, and *IRAK1/MECP2*).

**[0161]** An earlier candidate gene study identified *MECP2* (Sawalha, A.H. et al., PLoS ONE 3:e1727 (2008)) as a potential risk allele for SLE. However, in the current dataset, SNPs near *IRAK1*, a gene critical for toll-like receptor 7 and 9 signaling and located within the identified region of linkage disequilibrium surrounding *MECP2*, showed the strongest evidence of association. Similar findings were recently reported (Jacob, C.O. et al., Proc. Natl. Acad. Sci. USA (2009)), and further work will be needed to determine the causal allele in the *IRAK1/MECP2* locus. We found additional evidence of association for 3 loci – *TYK2*, *ICA1* and *NMNAT2* – that had previously shown significant but not genome-wide level evidence for association. (Harley, J.B. et al., Nat. Genet. 40:204-10 (2008); Sigurdsson, S. et al., Am J Hum Genet 76:528-37 (2005)). For four previously implicated variants – *LYN*, *SCUBE1*, *TLR5* and *LY9* – no evidence of association was observed in the combined dataset.

**[0162]** To identify novel SLE risk loci, we examined a total of 3,188 SNPs from 2,446 distinct loci that showed evidence of association to SLE in our genome-wide dataset (Hom, G. et al., N Engl J Med 358, 900-9 (2008)), which comprised 502,033 SNPs genotyped in 1,310 SLE cases and an expanded set of 7,859 controls. Using this dataset, we imputed  $> 2.1$

M variants using Phase II HapMap CEU samples as a reference (see Methods above), and generated a rank-ordered list of association statistics. Variants with  $P < 0.05$  were selected for possible inclusion on the custom replication array. For efficient genotyping, we identified groups of correlated variants ( $r^2 > 0.2$ ), followed by selection of at least two SNPs from each group where the lowest  $P$  value was  $< 0.001$ . For the remaining groups, the SNP with the lowest  $P$  value in the group was included. In the replication samples, we calculated the association statistics (see Methods) and observed a significant enrichment of the replication results relative to the expected null distribution. Excluding the previously reported SLE risk alleles, there were 134 loci with a  $P < 0.05$  (expected 64,  $P = 2 \times 10^{-15}$ ) and 12 loci with a  $P < 0.001$  (expected 1,  $P = 1 \times 10^{-9}$ ), suggesting the presence of true positives.

**[0163]** Each of Figures 2A-2E show the association results from the genome-wide association scan plotted on the  $y$  axis versus genomic position on the  $x$  axis within a 500 kb region surrounding the loci defined by *TNIP1* (Fig. 2A), *PRDM1* (Fig. 2B), *JAZF1* (Fig. 2C), *UHFR1BP1* (Fig. 2D), and *IL-10* (Fig. 2E). The meta-analysis  $P$  value for the most associated marker is indicated by a filled square in each of Figs. 2A-2E. For each of Figs. 2A-2E,  $P$  values from the genome scan are marked to indicate LD to the genome-wide associated variant: stippled circle signifies  $r^2 > 0.8$ ; dashed circle,  $r^2 > 0.5$ ; striped circle,  $r^2 > 0.2$ ; and open circle,  $r^2 < 0.2$ . Along the bottom of each of Figs. 2A-2E, the recombination rate from the CEU HapMap (solid black line) and the known human genes indicated under each plot. In Fig. 2B (*PRDM1*), a previously reported and independent SLE risk locus at the nearby ATG5 gene is indicated (rs2245214) by the solid black circle. Fig. 2F shows a histogram of the  $P$  values of 1256 independent SNPs ( $r^2 < 0.1$  to any other SNP in the array) in the 1,963 case and 4,329 control replication samples. Under a null distribution, the expected density of results is indicated by the dashed line in Fig. 2F. As indicated in Fig. 2F, a significant enrichment of results less than  $P < 0.05$  was observed.

**[0164]** Accordingly, the replication study identified 5 novel SLE risk loci with a combined  $P$  value that exceeded the genome-wide threshold for significance ( $P < 5 \times 10^{-8}$ ): *TNIP1*, *PRDM1*, *JAZF1*, *UHFR1BP1*, and *IL10*. Detailed statistical associations for these and other loci are shown below in Table 4.

**[0165]** A variant, rs7708392, on 5q33.1 that resides within an intron of TNF-Alpha Induced Protein 3 (TNFAIP3)-Interacting Protein 1 (*TNIP1*) was significantly associated with SLE in all three cohorts and had a combined  $P = 3.8 \times 10^{-13}$  (Figure 2A). Variants near *TNIP1* were recently found to contribute to risk of psoriasis (Nair, R.P. et al., Nat Genet

41:199-204 (2009)), however the SLE and psoriasis variants are separated by 21 Kb and appear to be distinct genetic signals ( $r^2 = 0.001$ ). TNIP1 and TNFAIP3 are interacting proteins (Heyninck, K., et al., FEBS Lett 536:135-40 (2003)), however, the precise role of TNIP1 in regulating TNFAIP3 is unknown. The association of multiple distinct variants near TNFAIP3 with SLE (Graham, R.R. et al., Nat. Genet. 40(9):1059-61 (2008), Musone, S.L. et al., Nat. Genet. 40(9):1062-64 (2008)), rheumatoid arthritis (Plenge, R.M. et al., Nat Genet 39:1477-82 (2007)), psoriasis (Nair, R.P. et al., Nat Genet 41:199-204 (2009)) and type I diabetes (Fung, E.Y. et al., Genes Immun 10:188-91 (2009)) suggests this pathway has an important role in the regulation of autoimmunity.

**[0166]** A second confirmed risk variant (rs6568431,  $P = 7.12 \times 10^{-10}$ ) was identified in an intergenic region between PR Domain containing 1, with ZNF domain (*PRDM1*, also known as *BLIMPI*) and APG5 autophagy 5-like (*ATG5*). The signal at rs6568431 appears to be distinct from the previously reported SLE risk allele within *ATG5*, rs2245214 (Harley, J.B. et al., Nat Genet 40:204-10 (2008)) (see Table 4), as rs6568431 has an  $r^2 < 0.1$  with rs2245214, and rs2245214 remains significantly associated with SLE ( $P < 1 \times 10^{-5}$ ) after conditional logistic regression incorporating rs6568431 (Figure 2B).

**[0167]** The promoter region of Juxtaposed with Another Zinc Finger gene 1 (*JAZF1*) is a third new confirmed SLE locus (rs849142,  $P=1.54 \times 10^{-9}$ ) (Figure 2C). Of interest, this same variant was previously linked to risk of type-2 diabetes (Zeggini, E. et al., Nat Genet 40:638-45 (2008)) and differences in height (Johansson, A. et al., Hum Mol Genet 18:373-80 (2009)). A separate prostate cancer allele near *JAZF1*, rs10486567, (Thomas, G. et al., Nat Genet 40:310-5 (2008)) showed no evidence for association in the current study.

**[0168]** A fourth novel risk locus in SLE is defined by a non-synonymous allele (R454Q) of ICBP90 binding protein 1 (*UHRFBP1*, rs11755393,  $P = 2.22 \times 10^{-8}$ ) (Figure 2D). This allele is a non-conservative amino acid change in a putative binding partner of UHRF1, a transcription and methylation factor linked to multiple pathways (Arita, K., et al., Nature 455:818-21 (2008)). The *UHRFBP1* risk allele is in a region of extended linkage disequilibrium which encompasses multiple genes, including small nuclear ribonucleoprotein polypeptide C (*SNRPC*), part of a RNA processing complex often targeted by SLE autoantibodies.

**[0169]** The fifth novel SLE locus identified is interleukin-10 (*IL10*; rs3024505,  $P = 3.95 \times 10^{-8}$ ) (Figure 2E). IL10 is an important immunoregulatory cytokine that functions to downregulate immune responses (Diveu, C., et al., Curr Opin Immunol 20:663-8 (2008)), and

variation in IL10 has inconsistently been reported to be associated with SLE (Nath, S.K., et al., Hum Genet 118:225-34 (2005)). The variant associated with SLE is identical to the SNP recently identified as contributing risk to ulcerative colitis (Franke, A. et al., Nat Genet 40:1319-23 (2008)) and type 1 diabetes (Barrett, J.C. et al., Nature Genetics 41:703 - 707 (2009)), suggesting the possibility of shared pathophysiology in the IL10 pathway across these disorders.

**[0170]** Using a significance threshold of  $P < 1 \times 10^{-5}$  in the combined replication sample, we identified 21 additional SLE candidate risk loci (Table 4). Less than one locus (0.01) with a  $P < 1 \times 10^{-5}$  was expected under a null distribution for the meta-analysis ( $P = 8 \times 10^{-77}$ ), suggesting that several of these loci are likely to be true positive loci. Interesting candidate genes in this list include: a) interferon regulatory factor 8 (*IRF8*), which was implicated in a previous GWAS (Graham, R.R. et al., Nat. Genet. 40(9):1059-61 (2008)) and whose family members *IRF5* and *IRF7* are within confirmed SLE risk loci; b) TAO kinase 3 (*TAOK3*), a missense allele (rs428073, N47S) of a kinase expressed in lymphocytes; c) lysosomal trafficking regulator (*LYST*), mutations of which cause the Chediak-Higashi syndrome in humans, a complex disorder characterized by a lymphoproliferative disorder; and d) interleukin 12 receptor, beta 2 (*IL12RB2*), a locus which includes *IL23R* and *SERPB1*, but appears distinct from the *IL23R* variants reported in the autoimmune diseases inflammatory bowel disease, psoriasis and ankylosing spondylitis (Duerr, R.H. et al., Science 314:1461-3 (2006)).

**[0171]** A remarkable feature of recent GWA studies is the large number of overlapping loci shared between different complex diseases (Zhernakova, A., et al., Nat Rev Genet 10:43-55 (2009)). We tested 42 variants from 35 loci that were previously reported as autoimmune disease risk alleles for association with SLE (Tables 6 and 7). No single locus had an unadjusted P value  $< 5 \times 10^{-8}$ , however, we found an enrichment of associated alleles. From the 35 loci tested (42 total variants), there were five alleles with an unadjusted  $P < 0.0004$  (less than one result expected by chance,  $P = 4.4 \times 10^{-12}$ ), and with a  $P < 0.05$  after a Bonferroni correction for the 35 pre-specified loci. For each of the five variants, the SLE associated allele matches the previously reported allele and has the same direction of effect (Table 6). We observed a highly significant association of a missense allele of *IFIH1* (rs1990760,  $P = 3.3 \times 10^{-7}$ ) that has previously been linked to type I diabetes and Grave's disease (Smyth, D.J. et al., Nat Genet 38:617-9 (2006); Sutherland, A. et al., J Clin Endocrinol Metab 92:3338-41 (2007)). We also observed an association with a missense

allele (R32Q) of complement factor B (CFB, rs641153) that resides in the HLA class III region and is a validated risk allele for age-related macular degeneration (Gold, B. et al., *Nat Genet* 38:458-62 (2006)). The SLE risk allele is not in significant linkage disequilibrium (LD) with other HLA region variants linked to SLE (DR2/DR3) and remained significant after conditional logistic regression analyses that incorporated DR2 and DR3. The HLA is a complex genetic region, but it is striking that the allele of SNP rs641153 has a protective effect nearly identical to the reported AMD risk allele (Gold, B. et al., *Nat Genet* 38:458-62 (2006)). Further study of the five candidate disease alleles is indicated.

**[0172]** In addition, Table 7 provides detailed summary statistics for the 42 variants identified in other autoimmune diseases. Of interest, variants from *CTLA4*, *IL23R*, *NOD2* and *CD40* that are significant risk factors in other autoimmune diseases appear to show no evidence of association to SLE.

**[0173]** Using 26 SLE risk alleles (21 previously reported loci in Table 2, plus the 5 novel SLE loci described above), several additional analyses were performed. Pair-wise interaction analysis with the confirmed loci was conducted and, consistent with previous literature from SLE (Harley, J.B. et al., *Nat Genet* 40:204-10 (2008)) and other complex diseases (Barrett, J.C. et al., *Nat Genet* 40:955-62 (2008)), no evidence for non-additive interactions was observed. Using conditional logistic regression analyses, we found no evidence for multiple independent alleles contributing to risk at any of the individual risk loci. We next estimated the percent of variance explained by each of the confirmed SLE risk alleles, using the methods described by Barrett et al. (Barrett, J.C. et al., *Nat Genet* 40:955-62 (2008)). *HLA-DR3*, *IRF5* and *STAT4* were each estimated to account for >1% of the genetic variance, while the remaining loci each accounted for less than 1% of the variance. Together, the 26 SLE risk loci explain an estimated 8% of the total genetic susceptibility to SLE.

**[0174]** Targeted replication of GWAS results is an efficient study design to confirm additional risk loci (Hirschhorn, J.N. et al., *Nat Rev Genet* 6:95-108 (2005)). There is little available data, however, as to the probability of replicating results that fall short of accepted P value criteria for genome-wide significance. In the current study, all variants with a P < 0.05 from the original GWAS studies were included for replication. As shown in Figure 3, the lower the P value in the GWAS study, the higher the probability of reaching candidate or confirmed status in the replication meta-analysis. Of interest, no candidate or confirmed results were obtained in the current study from the group of variants with a GWAS P between 0.05 and 0.01, despite accounting for ~50% of all variants tested in the replication. These

results may be useful in guiding future targeted study designs, although certainly the size of the original GWAS population, the replication sample size, the disease architecture, and the effect size of the candidate variants also need to be carefully considered in planning replication efforts.

**[0175]** These data provide further evidence that common variation in genes important for function of the adaptive and innate arms of the immune system are important in establishing risk for developing SLE. While each of the identified alleles accounts for only a fraction of the overall genetic risk, these and other ongoing studies are providing new insight into the pathogenesis of lupus and are suggesting new targets and pathways for drug discovery and development.

**Table 2. Replication results of previously reported SLE risk loci**

SNP	Chr	Critical Region	P Values			Risk Allele	Frequency	OR (95% C.I.)
			GWAS	US	Sweden			
Variants with a P < 5 x 10 <sup>-8</sup> in the current dataset								
rs3135394 <sup>a</sup>	6p21.32	32.027-32.874	7.8 x 10 <sup>-22</sup>	1.8 x 10 <sup>-26</sup>	8.3 x 10 <sup>-21</sup>	2.0 x 10 <sup>-60</sup>		1.98 (1.84-2.14)
rs7574865 <sup>a</sup>	2q32.2	191.609-191.681	3.0 x 10 <sup>-19</sup>	6.4 x 10 <sup>-16</sup>	2.7 x 10 <sup>-12</sup>	1.4 x 10 <sup>-41</sup>		1.57 (1.49-1.69)
rs2070197 <sup>a</sup>	7q32.1	128.276-128.476	n.a.	1.4 x 10 <sup>-16</sup>	4.1 x 10 <sup>-9</sup>	5.8 x 10 <sup>-24</sup>		1.88 (1.78-1.95)
rs11866650 <sup>a</sup>	16p11.2	31.195-31.277	5.3 x 10 <sup>-11</sup>	1.8 x 10 <sup>-5</sup>	9.2 x 10 <sup>-8</sup>	1.9 x 10 <sup>-20</sup>		1.43 (1.32-1.54)
rs2736340	8p23.1	11.331-11.488	5.5 x 10 <sup>-8</sup>	4.6 x 10 <sup>-9</sup>	0.0028	7.9 x 10 <sup>-17</sup>		1.35 (1.27-1.43)
rs5029937 <sup>a</sup>	6q23.3	138.174-138.284	1.0 x 10 <sup>-4</sup>	2.4 x 10 <sup>-7</sup>	3.1 x 10 <sup>-5</sup>	5.3 x 10 <sup>-13</sup>		1.71 (1.51-1.95)
rs2476601	1p13.2	113.963-114.251	3.3 x 10 <sup>-5</sup>	4.5 x 10 <sup>-5</sup>	1.5 x 10 <sup>-5</sup>	3.4 x 10 <sup>-12</sup>		1.35 (1.24-1.47)
rs4963128	11p15.5	0.485-0.664	0.0021	1.5 x 10 <sup>-5</sup>	8.7 x 10 <sup>-4</sup>	4.9 x 10 <sup>-9</sup>		1.20 (1.13-1.27)
rs2205960	1q25.1	171.454-171.523	9.5 x 10 <sup>-6</sup>	0.030	6.7 x 10 <sup>-4</sup>	6.3 x 10 <sup>-9</sup>		1.22 (1.15-1.30)
Variants with a previous report of P < 5 x 10 <sup>-8</sup>								
rs9271366 <sup>a</sup>	6p21.32	32.446-32.695	0.0079	7.4 x 10 <sup>-4</sup>	8.3 x 10 <sup>-5</sup>	1.4 x 10 <sup>-7</sup>		1.26 (1.18-1.36)
rs6920220 <sup>a</sup>	6q23.3	138.000-138.048	9.9 x 10 <sup>-4</sup>	5.2 x 10 <sup>-4</sup>	0.049	4.0 x 10 <sup>-7</sup>		1.17 (1.10-1.25)
rs2269368	Xq28	152.743-152.943	2.5 x 10 <sup>-5</sup>	n.a.	0.0049	7.5 x 10 <sup>-7</sup>		1.11 (1.01-1.22)
rs2431099	5q33.3	159.813-159.821	1.5 x 10 <sup>-5</sup>	0.16	0.047	1.6 x 10 <sup>-6</sup>		1.15 (1.09-1.22)
rs5754217	22q11.2	20.240-20.315	0.0060	8.4 x 10 <sup>-4</sup>	0.018	2.3 x 10 <sup>-6</sup>		1.20 (1.13-1.27)
rs2245214 <sup>a</sup>	6q21	106.749-106.876	0.032	4.3 x 10 <sup>-6</sup>	0.35	1.2 x 10 <sup>-5</sup>		1.15 (1.09-1.21)
rs10516487	4q24	102.930-103.134	0.097	0.091	0.0015	8.3 x 10 <sup>-4</sup>		1.11 (1.04-1.18)
rs2176082 <sup>a</sup>	3p14.3	58.214-58.443	0.010	0.012	0.0031	1.2 x 10 <sup>-5</sup>		1.17 (1.10-1.25)
rs1801274	1q23.3	159.724-159.746	4.1 x 10 <sup>-4</sup>	n.a.	n.a.	4.1 x 10 <sup>-4</sup>		1.16 (1.09-1.20)
Variants with a previous report of > 5 x 10 <sup>-8</sup>								
rs280519 <sup>a</sup>	19p13.2	10.387-10.430	7.1 x 10 <sup>-4</sup>	n.a.	0.036	7.4 x 10 <sup>-5</sup>		1.13 (1.06-1.21)
rs10156091	7p21.3	8.134-8.154	0.095	0.0031	8.7 x 10 <sup>-4</sup>	6.5 x 10 <sup>-4</sup>		1.16 (1.06-1.27)
rs2022013	1q25.3	181.538-181.670	0.26	2.05 x 10 <sup>-5</sup>	2.8 x 10 <sup>-4</sup>	0.0015		1.09 (1.03-1.16)
rs7829816	8q12.1	56.985-57.025	0.49	0.76	0.19	0.17		1.05 (0.96-1.17)
rs2071725	22q13.2	41.908-41.970	0.63	0.34	0.29	0.30		1.09 (0.98-1.20)
rs5744168 <sup>a</sup>	1q41	n.a.	1.00	0.40	0.67	0.67		1.02 (0.94-1.12)
rs509749	1q23.3	158.993-159.067	0.64	0.94	0.93	0.76		1.01 (0.91-1.12)

Critical Region here is defined as the minimal region containing variants with  $r^2 > 0.4$  in the HapMap CEU population and is reported in HG18 coordinates (Mb). P values calculated from indicated case/control population (GWAS: 1310 case and 7859 control, U.S.: 1129 case and 2991 control, Sweden 834 case and 12,188 control samples), and Combined P

value calculated as described in methods. Risk Allele is reported relative to + reference strand. Risk Allele Frequency is the frequency in control chromosomes. Odds ratio is the combined odds ratio as described in Methods above. <sup>a</sup> Indicates markers that were imputed, as described in Methods, in the GWAS samples and directly genotyped in the replication samples. <sup>b</sup> rs3135394 has an  $r^2 = 0.87$  to the HLA\*DR3 (DRB1\*0301) allele. <sup>c</sup> rs9271366 has an  $r^2 = 0.97$  to the HLA\*DR2 (DRB1\*1501) allele. See Table 3 for expanded summary statistics. N.A. = Not available; due to failure to pass QC measures (*TYK2*, *FCGR2A*, and *IRAK1/MECP2*), or the specific variant was not present in the genome-wide array (*TLR5* and *IRF5*). However, rs2070197 (*IRF5* region) is in strong linkage disequilibrium (LD) with rs10488631, which had a  $P = 2 \times 10^{-11}$  in the genome scan.

Table 3. Allele frequencies in replication study of previously reported SLE risk loci.

SNP	Chr	Critical Region	Locus	GWAS				US				Sweden			
				Allele Frequency		Cases		OR		Controls		Allele Frequency		Cases	
				A1/A2	OR	Controls	Cases	OR	Controls	Cases	OR	Controls	Cases	OR	Controls
rs3135394	6p21.32	32.027-32.874	<i>HLA-DR3</i>	G/A	1.89	0.102	0.166	2.33	0.090	0.188	2.27	0.135	0.239	0.239	0.239
rs7574865	2q32.2	191.609-191.681	<i>STAT4</i>	T/G	1.57	0.233	0.314	1.54	0.217	0.300	2.03	0.208	0.347	0.347	0.347
rs2070197	7q32.1	128.276-128.476	<i>IRF5</i>	C/T	n.a.	n.a.	1.82	0.105	0.176	2.08	0.125	0.226	0.226	0.226	0.226
rs11860650	16p11.2	31.195-31.277	<i>ITGAM</i>	T/C	1.50	0.130	0.177	1.27	0.142	0.175	1.64	0.112	0.178	0.178	0.178
rs2736340	8p23.1	11.331-11.488	<i>BLK</i>	T/C	1.31	0.246	0.299	1.47	0.236	0.313	1.25	0.262	0.307	0.307	0.307
rs5029937	6q23.3	138.174-138.284	<i>TNFAIP3</i>	T/G	1.57	0.034	0.051	1.84	0.033	0.059	1.88	0.034	0.065	0.065	0.065
rs2476601	1p13.2	113.963-114.251	<i>PTPN22</i>	A/G	1.35	0.098	0.116	1.48	0.083	0.119	1.47	0.120	0.167	0.167	0.167
rs2245214	6q21	106.749-106.876	<i>ATG5</i>	G/C	1.10	0.370	0.393	1.31	0.353	0.416	1.05	0.407	0.420	0.420	0.420
rs4963128	11p15.5	0.485-0.664	<i>PHRF1</i>	C/T	1.16	0.673	0.698	1.28	0.660	0.712	1.27	0.685	0.734	0.734	0.734
rs2205960	1q25.1	171.454-171.523	<i>TNFSF4</i>	T/G	1.25	0.230	0.269	1.18	0.225	0.255	1.28	0.233	0.280	0.280	0.280
rs9271366	6p21.32	32.446-32.695	<i>HLA-DR2</i>	G/A	1.16	0.172	0.192	1.41	0.142	0.188	1.39	0.157	0.204	0.204	0.204
rs6920220	6q23.3	138.000-138.048	<i>TNFAIP3</i>	A/G	1.19	0.206	0.234	1.28	0.190	0.231	1.16	0.232	0.257	0.257	0.257
rs2269368	Xq28	152.743-152.943	<i>IRAK1/MECP2</i>	T/C	1.29	0.141	0.175	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
rs2431099	5q33.3	159.813-159.821	<i>PTTG1</i>	G/A	1.20	0.522	0.568	1.09	0.515	0.536	1.14	0.541	0.578	0.578	0.578
rs5754217	22q11.2	20.240-20.315	<i>UBE2L3</i>	T/G	1.16	0.188	0.213	1.23	0.191	0.225	1.22	0.231	0.268	0.268	0.268
rs2176082	3p14.3	58.214-58.443	<i>PXK</i>	A/G	1.13	0.284	0.309	1.21	0.274	0.314	1.22	0.308	0.351	0.351	0.351
rs280519	19p13.2	10.387-10.430	<i>TYK2</i>	A/G	1.16	0.477	0.507	n.a.	n.a.	n.a.	1.15	0.476	0.511	0.511	0.511
rs1801274	1q23.3	159.724-159.746	<i>FCGR2A</i>	G/A	1.16	0.500	0.537	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
rs10156091	7p21.3	8.134-8.154	<i>ICAI</i>	T/C	1.12	0.098	0.104	1.26	0.105	0.129	1.19	0.095	0.110	0.110	0.110
rs10516487	4q24	102.930-103.134	<i>BANK1</i>	G/A	1.08	0.694	0.712	1.10	0.698	0.716	1.20	0.722	0.758	0.758	0.758
rs2022013	1q25.3	181.538-181.670	<i>NMNAT2</i>	T/C	1.05	0.599	0.609	1.22	0.580	0.627	1.04	0.618	0.627	0.627	0.627
rs7829816	8q12.1	56.985-57.025	<i>LYN</i>	A/G	1.04	0.786	0.795	1.03	0.783	0.789	1.07	0.817	0.827	0.827	0.827
rs2071725	22q13.2	41.908-41.970	<i>SCUBE1</i>	G/A	1.03	0.859	0.870	1.12	0.859	0.873	1.01	0.887	0.889	0.889	0.889
rs5744168	1	n.a.	<i>TLR5</i>	G/A	n.a.	n.a.	0.93	0.947	0.943	1.19	0.920	0.932	0.932	0.932	0.932
rs509749	1q23.3	158.993-159.067	LY9	G/A	1.02	0.425	0.428	1.00	0.429	0.430	0.99	0.453	0.451	0.451	0.451

Critical Region here is defined as the minimal region containing variants with  $r^2 > 0.4$  in the HapMap CEU population and is reported in HG18 coordinates. Allele frequencies calculated from indicated case/control population (GWAS: 1310 case and 7859 control, US: 1129 case and 2991 control, Sweden 834 case and 12188 control samples). Combined: 3273 case and 12188 control samples). Alleles are reported relative to + reference strand, and all data refers to Allele 1 (A1). The odds ratio (OR) for each population is listed.

**Table 4. Novel SLE risk loci in the combined dataset.**

SNP	Chr.	Critical Region	P values			Locus	Risk Allele	Frequency	OR (95% C.I.)
			GWAS	US	Sweden				
Genome-wide significant loci									
rs7708392 <sup>a</sup>	5	150.419-150.441	4.5 x 10 <sup>-7</sup>	7.7 x 10 <sup>-4</sup>	1.2 x 10 <sup>-5</sup>	3.8 x 10 <sup>-13</sup>	TNIP1	C	0.24 1.27 (1.10-1.35)
rs6568431	6	106.675-106.705	6.1 x 10 <sup>-6</sup>	0.0016	0.0050	7.1 x 10 <sup>-10</sup>	PRDM1	A	0.38 1.20 (1.14-1.27)
rs849142 <sup>a</sup>	7	28.108-28.223	4.5 x 10 <sup>-7</sup>	0.10	5.4 x 10 <sup>-4</sup>	1.5 x 10 <sup>-9</sup>	JAZF1	T	0.49 1.19 (1.13-1.26)
rs11755393 <sup>a</sup>	6	34.658-35.090	0.0014	3.7 x 10 <sup>-4</sup>	5.1 x 10 <sup>-4</sup>	2.2 x 10 <sup>-8</sup>	UHRF1BP1	G	0.35 1.17 (1.10-1.24)
rs3024505	1	205.007-205.016	2.6 x 10 <sup>-6</sup>	0.062	1.8 x 10 <sup>-4</sup>	4.0 x 10 <sup>-8</sup>	IL10	A	0.16 1.19 (1.11-1.28)
Loci with combined P value < 1 x 10 <sup>-6</sup>									
rs10911363 <sup>a</sup>	1	181.672-181.816	2.0 x 10 <sup>-4</sup>	1.5 x 10 <sup>-5</sup>	0.52	9.5 x 10 <sup>-8</sup>	NCF2	T	0.27 1.19 (1.12-1.26)
rs12444486 <sup>a</sup>	16	84.548-84.576	3.5 x 10 <sup>-5</sup>	0.021	0.026	1.9 x 10 <sup>-7</sup>	IRF8	T	0.50 1.16 (1.10-1.23)
rs11013210 <sup>a</sup>	10	23.181-23.337	1.6 x 10 <sup>-5</sup>	0.013	0.12	2.0 x 10 <sup>-7</sup>	ARMC3	T	0.21 1.18 (1.11-1.26)
rs1874791 <sup>a</sup>	1	67.563-67.687	3.1 x 10 <sup>-5</sup>	0.012	0.11	3.4 x 10 <sup>-7</sup>	IL12RB2	A	0.18 1.18 (1.10-1.26)
rs9782955	1	233.893-234.107	6.4 x 10 <sup>-6</sup>	0.057	0.12	4.6 x 10 <sup>-7</sup>	LYST	C	0.74 1.18 (1.11-1.26)
rs7683537 <sup>a</sup>	4	185.805-185.914	1.6 x 10 <sup>-4</sup>	0.11	0.0013	7.6 x 10 <sup>-7</sup>	MLF1IP	T	0.82 1.23 (1.14-1.33)
rs428073	12	117.706-117.315	1.7 x 10 <sup>-5</sup>	0.22	0.0079	7.7 x 10 <sup>-7</sup>	TAOK3	T	0.69 1.18 (1.11-1.26)
rs497273 <sup>a</sup>	12	119.610-119.891	5.0 x 10 <sup>-5</sup>	0.068	0.021	8.2 x 10 <sup>-7</sup>	SPPL3	G	0.65 1.14 (1.08-1.21)
Loci with combined P value < 1 x 10 <sup>-5</sup>									
rs1861525	7	25.097-25.183	8.5 x 10 <sup>-5</sup>	0.16	0.0027	1.9 x 10 <sup>-6</sup>	CYCS	G	0.05 1.27 (1.12-1.45)
rs921916	7	50.193-50.205	4.8 x 10 <sup>-4</sup>	0.027	0.014	2.0 x 10 <sup>-6</sup>	IKZF1	C	0.18 1.15 (1.07-1.23)
rs7333671	13	73.177-73.198	2.2 x 10 <sup>-4</sup>	0.14	0.0027	2.2 x 10 <sup>-6</sup>	KLF12	G	0.08 1.22 (1.11-1.34)
rs12992463	2	22.312-22.464	2.1 x 10 <sup>-5</sup>	0.23	0.023	2.6 x 10 <sup>-6</sup>	—	A	0.50 1.12 (1.06-1.19)
rs12620999	2	237.616-237.770	1.6 x 10 <sup>-5</sup>	0.040	0.45	3.1 x 10 <sup>-6</sup>	COPS8	C	0.19 1.13 (1.06-1.21)
rs5034225 <sup>a</sup>	11	118.079-118.198	0.0012	3.3 x 10 <sup>-4</sup>	0.43	3.3 x 10 <sup>-6</sup>	DDX6	C	0.20 1.16 (1.08-1.24)
rs10742326 <sup>a</sup>	11	34.733-34.809	1.4 x 10 <sup>-4</sup>	0.017	0.21	3.6 x 10 <sup>-6</sup>	APIP	G	0.59 1.14 (1.08-1.21)
rs4766921 <sup>a</sup>	12	117.835-117.883	4.6 x 10 <sup>-5</sup>	n.a.	0.036	4.6 x 10 <sup>-6</sup>	KIAA1853	G	0.67 1.18 (1.09-1.27)
rs11951576 <sup>a</sup>	5	6.741-6.866	2.5 x 10 <sup>-5</sup>	0.42	0.014	4.6 x 10 <sup>-6</sup>	POLS/SRD5A	C	0.69 1.14 (1.08-1.22)
rs6438700	3	123.355-123.454	7.4 x 10 <sup>-5</sup>	0.23	0.020	5.5 x 10 <sup>-6</sup>	CD86	C	0.82 1.18 (1.09-1.27)
rs6486730 <sup>a</sup>	12	127.830-127.840	8.2 x 10 <sup>-5</sup>	0.16	0.049	6.9 x 10 <sup>-6</sup>	SLC15A4	G	0.41 1.13 (1.07-1.19)
rs4748857 <sup>a</sup>	10	23.529-23.654	2.2 x 10 <sup>-4</sup>	0.68	1.3 x 10 <sup>-4</sup>	6.9 x 10 <sup>-6</sup>	C10orf67	C	0.73 1.16 (1.09-1.24)
rs3914167 <sup>a</sup>	5	39.426-39.454	1.8 x 10 <sup>-4</sup>	0.24	0.0081	7.6 x 10 <sup>-6</sup>	DAB2/C9	G	0.27 1.15 (1.09-1.23)

Samples, critical region, P values, risk alleles, and odds ratios are as defined in the Table 2 legend. <sup>a</sup> Indicates markers that were imputed, as described in Methods above, from the GWAS samples and directly genotyped in the replication samples. See Table 5 for expanded summary statistics.

**Table 5. Additional summary statistics for significant SLE risk loci in the combined dataset.**

SNP	Chr	Critical Region	Locus	GWAS				US				Sweden			
				Allele Frequency		OR	Cases	Controls	OR	Cases	Controls	OR	Cases	Controls	Cases
				A1/A2	Controls							OR	Cases	Controls	Allele Frequency
rs7708392	5	150.419-150.441	TNIP1	C/G	1.28	0.232	0.279	1.19	0.267	0.302	1.37	0.256	0.324	0.256	0.324
rs6568431	6	106.675-106.705	PRDM1	A/C	1.22	0.380	0.424	1.22	0.370	0.418	1.18	0.412	0.451	0.451	0.451
rs849142	7	28.108-28.223	JAZF1	T/C	1.23	0.490	0.542	1.11	0.491	0.516	1.25	0.499	0.552	0.552	0.552
rs11755393	6	34.658-35.090	UHRF1BP1	G/A	1.15	0.354	0.386	1.15	0.347	0.380	1.27	0.326	0.376	0.376	0.376
rs3024505	1	205.007-205.016	IL10	A/G	1.28	0.166	0.196	1.14	0.152	0.169	1.21	0.150	0.176	0.176	0.176
rs10911363	1	181.672-181.816	NCF2	T/G	1.21	0.274	0.307	1.27	0.273	0.323	1.05	0.275	0.293	0.293	0.293
rs12444486	16	84.548-84.576	IRF8	T/C	1.19	0.507	0.550	1.11	0.501	0.528	1.15	0.482	0.526	0.526	0.526
rs11013210	10	23.181-23.337	ARMC3	T/C	1.27	0.199	0.234	1.17	0.229	0.257	1.13	0.225	0.243	0.243	0.243
rs1874791	1	67.563-67.687	IL12RB2	A/G	1.25	0.188	0.225	1.09	0.188	0.202	1.15	0.146	0.163	0.163	0.163
rs9782955	1	233.893-234.107	LYST	C/T	1.25	0.737	0.777	1.12	0.744	0.766	1.15	0.765	0.788	0.788	0.788
rs7683537	4	185.805-185.914	MLF1P	T/C	1.23	0.811	0.843	1.13	0.832	0.848	1.34	0.834	0.872	0.872	0.872
rs428073	12	117.706-117.315	TAOK3	T/C	1.22	0.691	0.730	1.07	0.694	0.708	1.31	0.682	0.738	0.738	0.738
rs497273	12	119.610-119.891	SPPL3	G/C	1.19	0.649	0.690	1.03	0.663	0.670	1.16	0.678	0.660	0.660	0.660
rs1861525	7	25.097-25.183	CYCS	G/A	1.52	0.054	0.068	1.14	0.041	0.047	1.96	0.017	0.032	0.032	0.032
rs921916	7	50.193-50.205	IKZF1	C/T	1.20	0.187	0.211	1.08	0.189	0.200	1.27	0.152	0.185	0.185	0.185
rs7333671	13	73.177-73.198	KLF12	G/A	1.32	0.085	0.107	1.08	0.082	0.088	1.35	0.066	0.087	0.087	0.087
rs129992463	2	22.312-22.464	LOC645949	A/C	1.20	0.499	0.538	1.04	0.510	0.521	1.15	0.495	0.531	0.531	0.531
rs12620999	2	237.616-237.770	COPS8	C/T	1.27	0.190	0.217	1.12	0.180	0.198	1.03	0.185	0.190	0.190	0.190
rs503425	11	118.079-118.198	DDX6	C/T	1.18	0.206	0.233	1.20	0.194	0.224	1.06	0.198	0.206	0.206	0.206
rs10742326	11	34.733-34.809	APIP	G/A	1.18	0.585	0.625	1.11	0.591	0.617	1.09	0.577	0.601	0.601	0.601
rs4766921	12	117.835-117.883	KIAA1853	G/A	1.22	0.668	0.707	n.a.	n.a.	n.a.	1.15	0.662	0.689	0.689	0.689
rs11951576	5	6.741-6.866	POLSSRD5A	C/T	1.22	0.686	0.727	1.04	0.691	0.700	1.19	0.669	0.701	0.701	0.701
rs6438700	3	123.355-123.454	CD86	C/T	1.25	0.823	0.854	1.05	0.826	0.834	1.23	0.821	0.851	0.851	0.851
rs6486730	12	127.830-127.840	SLC15A4	G/A	1.19	0.405	0.446	1.06	0.420	0.436	1.14	0.422	0.450	0.450	0.450
rs4748857	10	23.529-23.654	C10orf67	C/T	1.22	0.715	0.741	1.10	0.763	0.780	1.35	0.742	0.791	0.791	0.791
rs3914167	5	39.426-39.454	DAB2/C9	G/C	1.19	0.274	0.312	1.08	0.276	0.291	1.20	0.262	0.294	0.294	0.294

Critical Region here is defined as the minimal region containing variants with  $r^2 > 0.4$  in the HapMap CEU population and is reported in HG18 coordinates. Allele frequencies calculated from indicated case/control population (GWAS: 1310 case and 7859 control, US: 1129 case and 2991 control, Sweden 834 case and 1338 control, Combined: 3273 case and 12,188 control samples). Alleles are reported relative to + reference strand, and all data refers to Allele 1 (A1). The odds ratio (OR) for each population is listed.

**Table 6. Candidate autoimmune loci with evidence of association to SLE.**

SNP	Locus	Chr	GWAS	US	Sweden	P Values		Combined	Risk Allele	OR	Phenotype	References
						Corrected	Allele Frequency					
rs1990760	<i>IFIH1</i>	2	3.2 x 10 <sup>-5</sup>	0.015	0.0039	3.34 x 10 <sup>-7</sup>	1.12 x 10 <sup>-5</sup>	T	0.60	1.17	T1D, Grave's	Nat Genet 38:617-9 (2006); J Clin Endocrinol Metab 92:3338-41 (2007)
rs641153 <sup>a</sup>	<i>CFB</i>	6	0.0079	n.a.	0.0011	1.4 x 10 <sup>-4</sup>	0.0049	G	0.91	1.30	AMD	Nat Genet 38:458-62 (2006); J Clin Endocrinol Metab 94:231-235 (2009); J Clin Endocrinol Metab 93:3310-7 (2008); Genes Immun 10:15-7 (2009)
rs12708716 <sup>a</sup>	<i>CLEC16A</i>	16	0.15	1.3 x 10 <sup>-4</sup>	0.062	1.6 x 10 <sup>-4</sup>	0.0056	A	0.64	1.16	T1D, Addison's, MS	Nat Genet 41:199-204 (2009); Nat Genet 40:710-2 (2008)
rs6887695 <sup>a</sup>	<i>IL12B</i>	5	0.014	0.04	0.03	1.7 x 10 <sup>-4</sup>	0.0060	G	0.68	1.13	PS, IBD	J Clin Endocrinol Metab 93:3310-7 (2008); Nat Genet 40:395-402 (2008); N Engl J Med 359:2767-77 (2008)
rs17696736	<i>SH2B3</i>	12	0.0036	0.12	0.19	4.0 x 10 <sup>-4</sup>	0.014	T	0.50	1.08	T1D, Celiac, SLE	Nat Genet 40:395-402 (2008); N Engl J Med 359:2767-77 (2008)

All alleles in the table were either identical to the reported variants or have  $r^2 > 0.8$  to the reported variant and were the same risk allele with the same direction of effect. Position (basepairs) is reported in HG18 coordinates. Samples, individual and combined P values, risk allele frequency and OR are as described in Table 2 legend. Combined-Corrected P value is the Bonferroni corrected P value for the 35 previously reported risk loci. Other autoimmunity associations: T1D = Type 1 diabetes, AMD = age-related macular degeneration MS = multiple sclerosis IBD = inflammatory bowel disease and PS = psoriasis. See Table 7 for expanded summary statistics and a complete list of variants tested. <sup>a</sup> Indicates markers that were imputed, as described in Methods, from the GWAS samples and directly genotyped in the replication samples.

Table 7 (part 1). Confirmed autoimmune disease loci.

SNP	Chr.	Position	Locus	GWAS			US		
				A1/A2	P value	OR	Controls	Cases	P value
rs1990760	2	162832297	IFIH1	T/C	3.2 x 10 <sup>-4</sup>	1.17	0.600	0.638	1.17
rs641153	6	32022159	CFB	G/A	0.0079	1.22	0.910	0.926	n.a.
rs12708716	16	11087374	CLEC16A	A/G	0.15	1.06	0.635	0.651	1.3 x 10 <sup>-4</sup>
rs6887695	5	158755223	IL12B	G/C	0.014	1.12	0.683	0.706	0.040
rs17696736	12	110971201	C12orf30	G/A	0.0081	1.12	0.449	0.474	0.16
rs3184504	12	110368991	SH2B3	T/C	0.0036	1.13	0.503	0.530	0.12
rs2812378	9	34700260	CCL21	G/A	0.003	1.14	0.322	0.349	0.79
rs3761847	9	122730060	TRAF1	G/A	0.034	1.10	0.411	0.432	0.20
rs6899540	6	43866302	VEGFA	C/A	8.1 x 10 <sup>-4</sup>	1.22	0.172	0.196	0.90
rs547154	6	32018917	C2	T/G	n.a.	n.a.	n.a.	n.a.	0.28
rs12044852	1	116889302	CD58	C/A	0.099	1.12	0.886	0.893	0.25
rs254251	18	12769947	PTPN2	G/T	0.15	1.09	0.152	0.162	n.a.
rs6897932	5	35910332	IL7R	C/T	0.18	1.06	0.740	0.751	0.25
rs2230799	19	6669387	C3	C/G	n.a.	n.a.	n.a.	n.a.	1.05
rs3732378	3	39282166	CX3CR1	G/A	0.13	1.09	0.833	0.843	0.063
rs1678542	12	56254982	KIF5A	C/G	0.051	1.09	0.624	0.642	0.94
rs1136287	17	1620026	SERPINF1	T/C	0.64	1.02	0.641	0.637	0.19
rs12247631	10	52485603	PRKG1	A/C	0.32	1.56	0.004	0.004	0.004
rs2227306	4	74825919	IL8	T/C	0.036	1.11	0.407	0.426	0.42
rs12521868	5	131812292	LOC441108	T/G	0.085	1.08	0.424	0.440	0.87
rs10490924	10	124204438	ARMS2	G/T	0.13	1.09	0.787	0.798	0.56
rs1793004	11	20655505	NELL1	G/C	0.81	1.01	0.758	0.759	0.25
rs10223965	7	92111514	CDK6	C/T	0.033	1.12	0.802	0.817	0.42
rs1410996	1	194963556	CFH	A/G	0.08	1.08	0.414	0.440	0.87
rs3087243	2	20447164	CTLA4	G/A	0.30	1.04	0.567	0.580	0.86
rs2292239	12	54768447	ERBB3	T/G	0.72	1.02	0.329	0.329	0.11
rs12722489	10	6142018	IL2RA	C/T	0.89	1.01	0.849	0.851	n.a.
rs9332739	6	32011783	C2	C/G	0.92	1.01	0.048	0.050	n.a.
rs2076756	16	49314382	NOD2	G/A	0.44	1.04	0.273	0.280	0.71
rs16853571	4	41447887	PHOX2B	C/A	0.51	1.06	0.065	0.067	0.79
rs4810485	20	44181354	CD40	T/G	0.37	1.04	0.264	0.274	n.a.
rs9340799	6	152205074	ESR1	A/G	0.17	1.06	0.646	0.659	0.28
rs3793784	10	50417545	ERCC6	C/G	0.54	1.03	0.402	0.408	0.42
rs2240340	1	17535226	PAD14	C/T	0.64	1.02	0.579	0.585	0.13
rs7517847	1	67454257	IL23R	T/G	0.79	1.01	0.567	0.567	0.86
Variants in LD with above loci									
rs1061170	1	194925860	CFH	T/C	n.a.	n.a.	n.a.	n.a.	n.a.
rs2234693	6	152205028	ESR1	T/C	n.a.	n.a.	n.a.	0.403	0.972
rs1136287	17	1620026	SERPINF1	T/C	0.642	1.021	0.637	0.190	1.023
rs3024997	6	43853085	VEGFA	A/G	n.a.	n.a.	n.a.	0.977	0.964

rs3212227	5	158675528	IL12B	T/G	0.000	1.220	0.792	0.821	0.407	1.059	1.059	0.784	0.794
rs2339898	10	53379358	PRKG1	C/T	0.626	1.022	0.338	0.347	0.190	1.051	1.051	0.338	0.349
rs42041	7	92084680	CDK6	G/C	0.570	1.028	0.267	0.269	0.790	0.966	0.966	0.258	0.251

Table 7 (part 2). Confirmed autoimmune disease loci.

SNP	Chr.	Position	Locus	Sweden			Replication		Combined P value
				A1/A2	P value	OR	Controls	Cases	
rs1990760	2	162832297	IFIH1	T/C	0.0039	1.17	0.609	0.645	$2.6 \times 10^{-4}$
rs641153	6	32022159	CFB	G/A	0.0011	1.47	0.915	0.939	$3.3 \times 10^{-7}$
rs12708716	16	11087374	CLEC16A	A/G	0.062	1.14	0.694	0.725	$1.4 \times 10^{-4}$
rs6887695	5	158755223	IL12B	G/C	0.030	1.16	0.664	0.700	$1.6 \times 10^{-6}$
rs17696736	12	110971201	C12orf30	G/A	0.019	1.16	0.437	0.474	$1.7 \times 10^{-6}$
rs3184504	12	110368991	SH2B3	T/C	0.19	1.09	0.487	0.508	$2.7 \times 10^{-4}$
rs2812378	9	34700260	CCL21	G/A	0.061	1.14	0.333	0.354	$4.0 \times 10^{-6}$
rs3761847	9	122730060	TRAF1	G/A	0.12	1.08	0.456	0.475	$1.8 \times 10^{-4}$
rs6899540	6	43866302	VEGFA	C/A	0.68	1.04	0.176	0.180	0.0041
rs547154	6	32018917	C2	T/G	0.0012	0.65	0.085	0.057	0.0051
rs12044852	1	116889302	CD58	C/A	0.33	1.10	0.872	0.883	0.026
rs254251	18	12769947	PTPN2	G/T	0.077	1.16	0.154	0.178	0.037
rs6897932	5	35910332	IL7R	C/T	0.23	1.06	0.712	0.725	0.038
rs223099	19	6669387	C3	C/G	0.081	0.85	0.205	0.179	0.011
rs3732378	3	39282166	CX3CR1	G/A	0.24	0.90	0.844	0.829	0.013
rs1678542	12	56254982	KIF5A	C/G	0.58	1.04	0.581	0.589	0.019
rs1136287	17	1620026	SERPINF1	T/C	0.16	1.05	0.637	0.648	0.012
rs12247631	10	52485603	PRKG1	A/C	0.27	n.a.	0.000	0.001	0.081
rs2227306	4	74825919	IL8	T/C	0.57	1.04	0.461	0.463	0.093
rs12521868	5	131812292	LOC441108	T/G	0.65	1.03	0.418	0.415	0.042
rs10490924	10	124204438	ARMS2	G/T	0.58	0.96	0.768	0.760	0.095
rs1793004	11	20655505	NELL1	G/C	0.24	1.09	0.725	0.746	0.025
rs10223965	7	92111514	CDK6	C/T	0.69	0.97	0.797	0.787	0.16
rs1410996	1	194963556	CFH	A/G	0.57	1.04	0.408	0.415	0.16
rs3087243	2	204447164	CTLA4	G/A	0.43	1.08	0.614	0.630	0.21
rs2292239	12	54768447	ERBB3	T/G	0.96	1.00	0.330	0.324	0.14
rs12722489	10	6142018	IL2RA	C/T	0.042	1.19	0.808	0.835	0.22
rs9332739	6	32011783	C2	C/G	0.037	1.36	0.044	0.059	0.23
rs2076756	16	49314382	NOD2	G/A	0.78	1.01	0.200	0.203	0.25
rs16853571	4	41447887	PHOX2B	C/A	0.33	1.20	0.056	0.067	0.27
rs4810485	20	44181354	CD40	T/G	0.85	0.99	0.246	0.249	0.31
rs9340799	6	152205074	ESR1	A/G	0.60	1.04	0.680	0.694	0.49
rs3793784	10	504117545	ERCC6	C/G	0.23	1.08	0.385	0.395	0.61
rs2240340	1	17535226	PAD14	C/T	0.91	0.99	0.594	0.585	0.64
rs7517847	1	67454257	IL23R	T/G	0.33	0.98	0.531	0.525	0.80
Variants in LD with above loci									
rs1061170	1	194925860	CFH	T/C	0.339	0.914	0.404	0.382	0.339
rs2234693	6	152205028	ESR1	T/C	0.719	0.993	0.556	0.555	0.375
rs1136287	17	1620026	SERPINF1	T/C	0.159	1.051	0.636	0.648	0.118
rs3024997	6	43853085	VEGFA	A/G	0.662	1.006	0.293	0.294	0.847

rs3212227	5	158675528	IL12B	T/G	0.636	1.042	0.810	0.817	0.342	4 x10 <sup>-4</sup>
rs2339898	10	53379358	PRKG1	C/T	0.789	1.010	0.315	0.309	0.366	0.341
rs42041	7	92084680	CDK6	G/C	0.049	0.913	0.268	0.239	0.170	0.661

Position (basepairs) is reported in HG18 coordinates. P values calculated from indicated case/control population (GWAS: 1310 case and 7859 control, US: 1129 case and 2991 control, Sweden 834 case and 1338 control, Combined: 3273 case and 12,188 control samples), and Combined P value calculated as described in the Methods above. The Replication P value refers to the meta P values for the combined U.S. and Swedish samples. Alleles are reported relative to + reference strand, and all data refers to Allele 1 (A1). The odds ratio (OR) for each population is listed.

## Example 2

### Re-sequencing and Identification of the Causal Allele for *BLK*

[0176] As discussed above, *BLK* has been identified as a risk locus associated with SLE that achieves genome-wide significance ( $P < 5 \times 10^{-8}$ ). To further characterize the genetic basis of this association and to identify causal allele(s), we carried out re-sequencing studies of the *BLK* locus and reporter gene expression assays as described below.

[0177] For the re-sequencing study, all 13 exons and 2.5 kb of upstream promoter sequence of the *BLK* locus in DNA isolated from 192 patients in the Autoimmune Biomarkers Collaborative Network (ABCOn) (Bauer et al., PLoS medicine 3(12):e491 (2006)), an NIH/NIAMS-funded repository, and 96 control individuals in New York Cancer Project (NYCP) (Mitchell et al., J. Urban Health 81:301-10 (2004)) was re-sequenced. Genomic DNA was whole-genome amplified according to the manufacturer's protocol (Qiagen, Valencia, CA., Cat. No. 150045) prior to sequencing.

[0178] The re-sequencing results showed that 17 mutations (10 non-synonymous, 7 synonymous) were found in the coding region of the *BLK* gene (Table 8). None of these mutations showed significantly higher frequencies in cases than in the controls. The overall frequency of non-synonymous mutation was not significantly higher in cases (14/191) than in controls (7/96).

[0179] In addition, multiple common variations were identified in the non-coding region of *BLK* (shown in Table 9). Three SNPs (rs4840568, rs1382568 [a tri-allelic SNP (A/C/G); C allele was previously identified as the risk allele], and rs922483 (SEQ ID NO: 13)) showed association with the loci previously identified from GWAS (Hom et al., N Engl J Med 358:900-09 (2008)) (rs13277113, odds ratio, 1.39,  $P=1\times 10^{-10}$ ) with  $r^2 > 0.5$ . Figure 4 shows a Linkage Disequilibrium (LD) block (shown in  $r^2$ ) within the promoter region of *BLK* that was generated using Haploview (software freely available at the URL [www.broadinstitute.org/seqdb/Haploview](http://www.broadinstitute.org/seqdb/Haploview); see Barrett J.C., et al., Bioinformatics 21:263-65 (2005)). The top portion of the figure shows a schematic diagram of the promoter region of *BLK* with the relative location of the identified SNPs indicated. The  $r^2$  value between the listed SNPs is shown in the boxes. The strength of LD between two SNPs is indicated by the  $r^2$  value provided in each box. The loci identified from GWAS (rs13277113)

and the three SNPs identified from re-sequencing (rs4840568, rs1382568, and rs922483 (SEQ ID NO: 13)) are indicated in black border at the top of the figure.

**[0180]** This re-sequencing study did not reveal any common variation in the coding region of *BLK*. Three common variants (rs4840568, rs1382568, and rs922483 (SEQ ID NO: 13)) at the promoter region, however, were identified as potential causal allele(s) of the biological effects of *BLK* associated with increased risk of SLE. Each of these variations was employed in luciferase reporter assays described in detail below to further characterize the association.

**Table 8.** Mutations in the *BLK* coding region

Exon	Amino Acid Change (Protein: NP_001706.2)	Nucleotide Change (mRNA: NM_001715.2)	dbSNP	dbSNP	Zygosity	Non-synonymous	Cases (n=191)	Controls (n=96)
2	39P>L	697_C>T	N/A	N/A	Heterozygous	Yes	1	0
4	71A>T	792_G>A	rs55758736	N/A	Heterozygous	Yes	6	4
4	75R>R	806_G>T	N/A	N/A	Heterozygous	No	1	0
4	86Q>Q	839_G>A	rs56185487	N/A	Heterozygous	No	2	0
6	131R>W	972_C>T	N/A	N/A	Heterozygous	Yes	2	0
6	137Q>Q	992_G>A	N/A	N/A	Heterozygous	No	0	1
7	180R>H	1120_G>A	N/A	N/A	Heterozygous	Yes	1	0
7	190S>S	1151_C>T	N/A	N/A	Homozygous	No	0	1
8	237P>P	1292_C>T	N/A	N/A	Heterozygous	No	1	1
8	238R>Q	1294_G>A	N/A	N/A	Heterozygous	Yes	1	0
10	325K>T	1555_A>C	N/A	N/A	Heterozygous	Yes	2	0
10	327D>V	1561_A>T	N/A	N/A	Heterozygous	Yes	0	1
10	331R>I	1573_G>T	N/A	N/A	Heterozygous	Yes	1	0
11	359R>C	1656_C>T	N/A	N/A	Heterozygous	Yes	0	1
12	425L>P	1855_T>C	N/A	N/A	Heterozygous	Yes	0	1
13	464L>L	1973_G>A	N/A	N/A	Heterozygous	No	1	0
13	474R>R	2003_C>T	N/A	N/A	Heterozygous	No	2	0

Non-synonymous mutation frequency	14/191	7/96
-----------------------------------	--------	------

**Table 9.** Common variations in the *BLK* non-coding region ('rs922483' disclosed as SEQ ID NO: 13).

Nucleo-tide Change	Chromosomal location	Chromo-some	dbSNP	Assoc. Allele	Case,Control RatioCounts (191,96)	Case,Control Frequencies	Chi square	P value	r^2 (with rs 13277113)
C>A	11386986	8	rs2251056	A	321:61, 150:42	0.840, 0.781	3.027	0.0819	0.066
C>T	11387925	8	N/A	T	8:374, 1:191	0.021, 0.005	2.05	0.1522	0.006
T>C	11388088	8	rs2736344	C	329:53, 149:43	0.861, 0.776	6.662	0.0098	0.072
C>G	11388131	8	rs9694294	G	323:59, 149:43	0.846, 0.776	4.225	0.0398	0.078
T>C	11388309	8	rs1382567	T	199:183, 93:99	0.521, 0.484	0.684	0.4083	0.335
<b>G&gt;A</b>	<b>11388429</b>	<b>8</b>	<b>rs4840568</b>	<b>A</b>	<b>125:257, 41:151</b>	<b>0.327, 0.214</b>	<b>8.033</b>	<b>0.0046</b>	<b>0.852</b>
<b>A&gt;C</b>	<b>11388630</b>	<b>8</b>	<b>rs1382568</b>	<b>C</b>	<b>121:261, 38:154</b>	<b>0.317, 0.198</b>	<b>9.01</b>	<b>0.0027</b>	<b>0.889</b>
A>G	11388631	8	rs1382568	A	200:182, 94:98	0.524, 0.490	0.59	0.4423	0.331
<b>C&gt;T</b>	<b>11389322</b>	<b>8</b>	<b>rs922483</b>	<b>T</b>	<b>137:245, 43:149</b>	<b>0.359, 0.224</b>	<b>10.768</b>	<b>0.001</b>	<b>0.741</b>
A>G	11389466	8	N/A	G	320:62, 148:44	0.838, 0.771	3.794	0.0514	0.059
C>T	11404079	8	N/A	C	274:108, 128:64	0.717, 0.667	1.56	0.2117	0.037
G>C	11404447	8	N/A	G	358:24, 176:16	0.937, 0.917	0.829	0.3626	0.018
C>T	11404452	8	N/A	T	55:327, 23:169	0.144, 0.120	0.637	0.4249	0.038
T>C	11404502	8	N/A	C	91:291, 45:147	0.238, 0.234	0.01	0.9186	0.001
T>C	11443842	8	N/A	T	196:184, 80:112	0.516, 0.417	5.019	0.0251	0.083
T>C	11451476	8	N/A	C	315:65, 150:38	0.829, 0.798	0.818	0.3657	0.016
A>G	11452981	8	rs4841557	A	158:222, 63:129	0.416, 0.328	4.135	0.042	0.187
C>T	11453006	8	rs4841558	C	157:223, 63:129	0.413, 0.328	3.897	0.0484	0.181
G>A	11455795	8	rs1042695	A	145:237, 59:133	0.380, 0.307	2.915	0.0878	0.179
G>A	11456175	8	N/A	A	335:45, 157:35	0.882, 0.818	4.325	0.0375	0.019
G>A	11456176	8	N/A	G	340:42, 157:35	0.890, 0.818	5.758	0.0164	0.015
C>T	11456182	8	rs4841561	T	146:234, 59:133	0.384, 0.307	3.282	0.07	0.177
C>T	11458793	8	rs10097015	T	160:222, 68:122	0.419, 0.358	1.967	0.1608	0.161
C>T	11459203	8	rs1042689	T	144:238, 62:130	0.377, 0.323	1.622	0.2028	0.161
G>A	11459455	8	N/A	G	213:169, 98:94	0.558, 0.510	1.145	0.2845	0.2
T>C	11459540	8	N/A	T	212:170, 100:92	0.555, 0.521	0.6	0.4385	0.219

**[0181]** Luciferase reporter gene assays were performed to investigate the effect of the three SNPs, rs4840568, rs1382568, and rs922483 (SEQ ID NO: 13) on *BLK*-mediated gene expression. An upstream sequence (-2256 to +55 bp) of *BLK* was amplified using genomic DNA from individuals that carry risk or non-risk haplotype. Each PCR product was cloned into pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA; Cat. No. K4500-01) and then sub-cloned into pGL4 luciferase reporter vector (Promega, Madison, WI; Cat. No. E6651). A construct that carries non-risk haplotype was used as template for mutagenesis (Stratagene, La Jolla, CA; Cat. No. 10519-5) to create various haplotypes.

**[0182]** The primers used in PCR amplification were as follows: forward: CCACCTCTTCCGCCTTCTCAT (SEQ ID NO.: 1); reverse: TTTCATGGCTTGTGGCTTCTGCC (SEQ ID NO.: 2). The primers used in mutagenesis are listed in Table 10 below.

**Table 10.** List of mutagenesis primers.

Primer	Sequence
rs4840568_G>A forward	GATCCAAGACTATGAAGAGAGAAGAGAGAGAGCCAC (SEQ ID NO.: 3)
rs4840568_G>A reverse	GTGGGCTCTCTCTCTCTCATAGTCTTGGATC (SEQ ID NO.: 4)
rs1382568_A>C forward	CCAGACACCACTCACCCCTCTAGATGTTGGAT (SEQ ID NO.: 5)
rs1382568_A>C reverse	ATCCCAACATCTAGAGGGGTGAGTGGTGTCTGG (SEQ ID NO.: 6)
rs1382568_A>G forward	CCAGACACCACTCACCGCTCTAGATGTTGGAT (SEQ ID NO.: 7)
rs1382568_A>G reverse	ATCCCAACATCTAGAGCGGTGAGTGGTGTCTGG (SEQ ID NO.: 8)
rs1382568_G>A forward	CCAGACACCACTCACCACTCTAGATGTTGGAT (SEQ ID NO.: 9)
rs1382568_G>A reverse	ATCCCAACATCTAGAGTGGTGAGTGGTGTCTGG (SEQ ID NO.: 10)
rs922483_C>T (SEQ ID NO: 13) forward	CGGGGGTGCTGCTACCTCTGTCTGC (SEQ ID NO.: 11)
rs922483_C>T (SEQ ID NO: 13) reverse	GCAGACAGAGGTAGCAGCACCCCCG (SEQ ID NO.: 12)

[0183] Renilla luciferase control reporter vector pRL-TK (Promega, Madison, WI; Cat. No. E2241) was used for normalization. The cell line BJAB (a continuous lymphoid cell line with characteristics of B cells (bone marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas; Klein et al., Proc. Natl. Acad. Sci. USA 71:3283-86 (1974)) or the Daudi cell line (American Type Culture Collection (ATCC) cat. No. CCL-213) was used for transfections. For each transfection,  $5 \times 10^6$  cells were transfected with 5  $\mu$ g of DNA of each vector using an Amaxa® Nucleofector® device (Lonza, Walkersville Inc., Walkersville, MD (Lonza Group Ltd., Switzerland); Cat. No. AAD-1001). Cell line Nucleofector® Kit L (Lonza, Cat. No. VCA-1005) was used for Daudi cells with Nucleofector® device Program A-030. Cell line Nucleofector® Kit V (Lonza, Cat. No. VCA-1005) was used for BJAB cells with Nucleofector® device Program T-020. All transfections were carried out either in duplicate or triplicate. Cells were incubated at 37°C for 16 hours following transfection. Following that incubation, cells were harvested and luciferase activity was measured using the Dual-

Luciferase® Reporter Assay System (Promega, Madison, WI; Cat. No. E1960) according to the manufacturer's instructions.

[0184] The effects of each of the SNPs rs4840568, rs1382568, and rs922483 (SEQ ID NO: 13) on *BLK*-mediated gene expression as measured in the luciferase reporter assay system described above are shown in Figure 5. The different haplotypes generated by mutagenesis were compared with non-risk (wild-type) haplotype 22-GAC (open bar in each of Figs. 5A-F) and risk haplotype 22-ACT (hatched bar in each of Figs. 5A-F).

[0185] Figs. 5A and 5B show that SNP rs922483 (C>T) (SEQ ID NO: 13) led to a significant effect on *BLK*-mediated gene expression in both BJAB (Fig. 5A) and Daudi cells (Fig. 5B). Compared to non-risk haplotype 22-GAC (open bar), haplotype 22-GAT showed reduced transcriptional activity by almost 50% in both cell lines. Haplotypes with T allele showed consistently lower activity than those with C alleles. Five independent experiments were done in BJAB cells and six independent experiments were done in Daudi cells. Data shown represent the mean +/- standard error of the mean (s.e.m.) in triplicate assays; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 (t-test).

[0186] Figs. 5C and 5D show that SNP rs1382568 (A>C/G>C) did not result in any significant effect on *BLK*-mediated expression in either cell line. Both haplotypes 22-GCC and 22-GGC (spotted bars) showed a similar level of luciferase activity compared to non-risk haplotype 22-GAC (open bar). Five independent experiments were done in BJAB cells and six independent experiments were done in Daudi cells. Data shown represent the mean +/- s.e.m. in triplicate assays; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, ns=not significant (t-test).

[0187] Figs. 5E and 5F show that SNP rs4840568 (G>A) did not result in a significant effect on *BLK*-mediated expression in BJAB cells or Daudi cells. The difference between haplotype 22-AAC (spotted bar) and non-risk haplotype 22-GAC (open bar) was not statistically significant in BJAB cells (Fig. 5E), but it was statistically significant in Daudi cells (Fig. 5F). The likelihood of A allele being a causal allele is greatly reduced given the fact that haplotype 22-ACC (spotted bar) did not show any defect in luciferase activity compared to the non-risk haplotype-GAC (open bar) (Fig. 5F). Data shown represent the mean +/- s.e.m. in triplicate assays; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001, ns=not significant (t-test).

[0188] It was shown previously that the (GT) repeat in the region upstream of the *BLK* promoter can function as an enhancer of *BLK* gene expression (Lin et al., J Biol Chem 270: 25968 (1995)). Therefore, we also tested whether the length of (GT) repeat can affect the transcriptional activity of the *BLK* promoter. To perform these experiments, genomic DNA samples from individuals that carry both 18 (GT) repeats (SEQ ID NO: 14) or 22 (GT) repeats (SEQ ID NO: 15) were selected for cloning using the strategy described above. Final vectors were sequenced to confirm they contained the correct length of (GT) repeats. As shown in Fig. 6, haplotypes with 18 (GT) repeats (SEQ ID NO: 14) displayed a similar level of transcriptional activity compared to those with 22 (GT) repeats (SEQ ID NO: 15) in the luciferase reporter assay. Data shown represent the mean +/- s.e.m in duplicate assays, ns=not significant (t-test).

[0189] In summary, these results of the *BLK* re-sequencing efforts and the results of the luciferase reporter gene assays indicate that SNP rs922483 (C>T) (Fig. 7, SEQ ID NO: 13) is the causal allele that results in decreased transcription of *BLK*, a biological effect which is associated with an increased risk of SLE. In addition, the results showed that the T allele of rs922483 (SEQ ID NO: 13) reduced the level of *BLK*-mediated gene expression by 50%.

[0190] It is interesting to note that rs922483 (SEQ ID NO: 13) resides in an evolutionarily conserved region in the first exon of *BLK* and within a possible human transcription initiation site. A consensus sequence for the human Inr motif has been identified as YYANWYY (IUPAC nucleotide code). Juven-Gershon et al. Dev. Biol. 339:225-229 (2010). In the SNP rs922483 (SEQ ID NO: 13), the second base in the Inr region is altered relative to the consensus motif. Accordingly, the SLE risk haplotype Inr sequence is CTACCTC while the "wild type" haplotype Inr sequence is CCACCTC. We suggest that the modification of the second base in the conserved Inr motif might alter the affinity of the TFIID transcription complex resulting in the observed difference in transcription described above.

## CLAIMS

## WHAT IS CLAIMED IS:

1. A method of identifying lupus in a subject, the method comprising detecting in a biological sample derived from the subject the presence of a variation in a SLE risk locus, wherein the SLE risk locus is *BLK*, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP), wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, and wherein the subject is suspected of suffering from lupus.
2. A method of identifying lupus in a subject, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP) for the at least one locus as set forth in Table 4, and wherein the subject is suspected of suffering from lupus.
3. The method of claim 2, wherein a variation is detected in at least two loci, or at least three loci, or at least four, or at least five loci, or at least ten loci, or at least 13 loci, or at 26 loci.
4. The method of claim 2, wherein the at least one locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*.
5. The method of claim 2, wherein the variation in the at least one locus comprises a SNP as set forth in Table 4.
6. A method of identifying lupus in a subject, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP) for the at least one locus as set forth in Table 6, and wherein the subject is suspected of suffering from lupus.
7. The method of claim 6, wherein a variation is detected in at least two loci, or at least three loci, or at least four, or at five loci.
8. The method of claim 6, wherein the at least one locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.

9. The method of claim 6, wherein the variation in the at least one locus comprises a SNP as set forth in Table 6.
10. The method of claim 1, comprising detecting a further variation in at least one SLE risk locus as set forth in Table 4, wherein the further variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4.
11. The method of claim 1, comprising detecting a further variation in at least one SLE risk locus as set forth in Table 6, wherein the further variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6.
12. The method of claim 10, comprising detecting a further variation in at least one SLE risk locus as set forth in Table 6, wherein the further variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6.
13. The method of claim 2, comprising detecting a further variation in at least one SLE risk locus as set forth in Table 6, wherein the further variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6.
14. The method of any one of claims 1-13, wherein the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.
15. A method for predicting responsiveness of a subject with lupus to a lupus therapeutic agent, the method comprising determining whether the subject comprises a variation in a SLE risk locus, wherein the SLE risk locus is *BLK*, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP), wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8, wherein the presence of the variation in the *BLK* locus indicates the responsiveness of the subject to the therapeutic agent.

16. A method for predicting responsiveness of a subject with lupus to a lupus therapeutic agent, the method comprising determining whether the subject comprises a variation in at least one SLE risk locus as set forth in Table 4, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP) for the at least one locus as set forth in Table 4, wherein the presence of the variation in the at least one locus indicates the responsiveness of the subject to the therapeutic agent.
17. The method of claim 16, wherein a variation is detected in at least two loci, or at least three loci, or at least four, or at least five loci, or at least ten loci, or at least 13 loci, or at 26 loci.
18. The method of claim 16, wherein the at least one locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*.
19. The method of claim 16, wherein the variation in the at least one locus comprises a SNP as set forth in Table 4.
20. A method for predicting responsiveness of a subject with lupus to a lupus therapeutic agent, the method comprising determining whether the subject comprises a variation in at least one SLE risk locus as set forth in Table 6, wherein the variation in the at least one locus occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP) for the at least one locus as set forth in Table 6, wherein the presence of the variation in the at least one locus indicates the responsiveness of the subject to the therapeutic agent.
21. The method of claim 20, wherein a variation is detected in at least two loci, or at least three loci, or at least four, or at five loci.
22. The method of claim 20, wherein the at least one locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.
23. The method of claim 20, wherein the variation in the at least one locus comprises a SNP as set forth in Table 6.
24. The method of claim 15, comprising determining whether the subject comprises a further variation in at least one SLE risk locus as set forth in Table 4, wherein the further variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 4.
25. The method of claim 15, comprising determining whether the subject comprises a further variation in at least one SLE risk locus as set forth in Table 6, wherein the further variation in the

at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6.

26. The method of claim 24, comprising determining whether the subject comprises a further variation in at least one SLE risk locus as set forth in Table 6, wherein the further variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6.

27. The method of claim 16, comprising determining whether the subject comprises a further variation in at least one SLE risk locus as set forth in Table 6, wherein the further variation in the at least one locus occurs at a nucleotide position corresponding to the position of a SNP for the at least one locus as set forth in Table 6.

28. A method of diagnosing or prognosing lupus in a subject, the method comprising detecting in a biological sample derived from the subject the presence of a variation in a SLE risk locus, wherein the SLE risk locus is *BLK*, wherein:

- (a) the biological sample is known to comprise, or is suspected of comprising, nucleic acid comprising a variation in the *BLK* locus;
- (b) the variation occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP), wherein the SNP is rs922483 (SEQ ID NO: 13), wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8; and
- (c) the presence of the variation in the *BLK* locus is a diagnosis or prognosis of lupus in the subject.

29. A method of diagnosing or prognosing lupus in a subject, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 4, wherein:

- (a) the biological sample is known to comprise, or is suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 4;
- (b) the variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 4; and
- (c) the presence of the variation in the at least one locus is a diagnosis or prognosis of lupus in the subject.

30. The method of claim 29, wherein a variation is detected in at least two loci, or at least three loci, or at least four, or at least five loci, or at least ten loci, or at least 13 loci, or at 26 loci.

31. The method of claim 29, wherein the at least one locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*.

32. The method of claim 29, wherein the variation in the at least one locus comprises a SNP as set forth in Table 4.

33. A method of diagnosing or prognosing lupus in a subject, the method comprising detecting in a biological sample derived from the subject the presence of a variation in at least one SLE risk locus as set forth in Table 6, wherein:

- (a) the biological sample is known to comprise, or is suspected of comprising, nucleic acid comprising a variation in at least one SLE risk locus as set forth in Table 6;
- (b) the variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6; and
- (c) the presence of the variation in the at least one locus is a diagnosis or prognosis of lupus in the subject.

34. The method of claim 33, wherein a variation is detected in at least two loci, or at least three loci, or at least four, or at five loci.

35. The method of claim 33, wherein the at least one locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.

36. The method of claim 33, wherein the variation in the at least one locus comprises a SNP as set forth in Table 6.

37. The method of claim 28, wherein:

- (a) the biological sample is known to comprise, or is suspected of comprising, nucleic acid comprising a further variation in at least one SLE risk locus as set forth in Table 4;
- (b) the further variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 4; and
- (c) the presence of the further variation in the at least one locus is a diagnosis or prognosis of lupus in the subject.

38. The method of claim 28, wherein:

- (a) the biological sample is known to comprise, or is suspected of comprising, nucleic acid comprising a further variation in at least one SLE risk locus as set forth in Table 6;
- (b) the further variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6; and
- (c) the presence of the further variation in the at least one locus is a diagnosis or prognosis of lupus in the subject.

39. The method of claim 37, wherein:

- (a) the biological sample is known to comprise, or is suspected of comprising, nucleic acid comprising a further variation in at least one SLE risk locus as set forth in Table 6;
- (b) the further variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6; and
- (c) the presence of the further variation in the at least one locus is a diagnosis or prognosis of lupus in the subject.

40. The method of claim 29, wherein:

- (a) the biological sample is known to comprise, or is suspected of comprising, nucleic acid comprising a further variation in at least one SLE risk locus as set forth in Table 6;
- (b) the further variation in the at least one locus comprises, or is located at a nucleotide position corresponding to, a SNP as set forth in Table 6; and
- (c) the presence of the further variation in the at least one locus is a diagnosis or prognosis of lupus in the subject.

41. The method of any one of claims 28-40, wherein the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

42. A method of treating a lupus condition in a subject in whom a genetic variation is known to be present at a nucleotide position corresponding to a single nucleotide polymorphism (SNP) in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13), the SLE risk locus is *BLK*, and wherein the variation is thymine at chromosomal location 11389322 on human chromosome

8, the method comprising administering to the subject a therapeutic agent effective to treat the condition.

43. A method of treating a lupus condition in a subject in whom a genetic variation is known to be present at a nucleotide position corresponding to a single nucleotide polymorphism (SNP) as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4, the method comprising administering to the subject a therapeutic agent effective to treat the condition.

44. A method of treating a lupus condition in a subject in whom a genetic variation is known to be present at a nucleotide position corresponding to a single nucleotide polymorphism (SNP) as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6, the method comprising administering to the subject a therapeutic agent effective to treat the condition.

45. A method of treating a subject having a lupus condition, the method comprising administering to the subject a therapeutic agent effective to treat the condition in a subject who has a genetic variation in a SLE risk locus, wherein the SLE risk locus is *BLK*, wherein the variation in the *BLK* locus occurs at a nucleotide position corresponding to the position of a single nucleotide polymorphism (SNP), wherein the SNP is rs922483 (SEQ ID NO: 13), and wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

46. A method of treating a subject having a lupus condition, the method comprising administering to the subject a therapeutic agent effective to treat the condition in a subject who has a genetic variation at a nucleotide position corresponding to a single nucleotide polymorphism (SNP) as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4.

47. The method of claim 46, wherein the at least one SLE risk locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*.

48. A method of treating a subject having a lupus condition, the method comprising administering to the subject a therapeutic agent effective to treat the condition in a subject who has a genetic variation at a nucleotide position corresponding to a single nucleotide polymorphism (SNP) as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6.

49. The method of claim 48, wherein the at least one SLE risk locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.

50. A method comprising manufacturing a lupus therapeutic agent, and packaging the agent with instructions to administer the agent to a subject who has or is believed to have lupus and

who has a genetic variation at a position corresponding to a single nucleotide polymorphism (SNP) in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13), the SLE risk locus is *BLK*, and wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

51. A method comprising manufacturing a lupus therapeutic agent, and packaging the agent with instructions to administer the agent to a subject who has or is believed to have lupus and who has a genetic variation at a position corresponding to a single nucleotide polymorphism (SNP) as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4.

52. A method comprising manufacturing a lupus therapeutic agent, and packaging the agent with instructions to administer the agent to a subject who has or is believed to have lupus and who has a genetic variation at a position corresponding to a single nucleotide polymorphism (SNP) as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6.

53. A method for selecting a patient suffering from lupus for treatment with a lupus therapeutic agent comprising detecting the presence of a genetic variation at a nucleotide position corresponding to a single nucleotide polymorphism (SNP) in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13), the SLE risk locus is *BLK*, and wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

54. A method for selecting a patient suffering from lupus for treatment with a lupus therapeutic agent comprising detecting the presence of a genetic variation at a nucleotide position corresponding to a single nucleotide polymorphism (SNP) as set forth in Table 4 in at least one SLE risk locus as set forth in Table 4.

55. The method of claim 54, wherein the at least one SLE risk locus is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, and *IL10*.

56. A method for selecting a patient suffering from lupus for treatment with a lupus therapeutic agent comprising detecting the presence of a genetic variation at a nucleotide position corresponding to a single nucleotide polymorphism (SNP) as set forth in Table 6 in at least one SLE risk locus as set forth in Table 6.

57. The method of claim 56, wherein the at least one SLE risk locus is selected from *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.

58. The method of any one of claims 53-57, wherein the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.

59. A method of assessing whether a subject is at risk of developing lupus, the method comprising detecting in a biological sample obtained from the subject, the presence of a genetic signature indicative of risk of developing lupus, wherein said genetic signature comprises a set of at least three single nucleotide polymorphisms (SNPs), each SNP occurring in a SLE risk locus as set forth in Table 4 and in Table 6.

60. The method of claim 59, wherein the genetic signature comprises a set of at least four SNPs, or at least five SNPs, or at least seven SNPs, or at least ten SNPs, or at least 15 SNPs, or at least 20 SNPs, or at least 30 SNPs.

61. The method of claim 59, wherein each of the SLE risk loci is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, *IL10*, *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.

62. The method of claim 58, wherein the genetic signature further comprises a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.


63. A method of diagnosing lupus in a subject, the method comprising detecting in a biological sample obtained from the subject, the presence of a genetic signature indicative of lupus, wherein said genetic signature comprises a set of at least three single nucleotide polymorphisms (SNPs), each SNP occurring in a SLE risk locus as set forth in Table 4 and in Table 6.

64. The method of claim 63, wherein the genetic signature comprises a set of at least four SNPs, or at least five SNPs, or at least seven SNPs, or at least ten SNPs, or at least 15 SNPs, or at least 20 SNPs, or at least 30 SNPs.

65. The method of claim 63, wherein each of the SLE risk loci is selected from *TNIP1*, *PRDM1*, *JAZF1*, *UHRF1BP1*, *IL10*, *IFIH1*, *CFB*, *CLEC16A*, *IL12B*, and *SH2B3*.

66. The method of claim 63, wherein the genetic signature further comprises a SNP in a SLE risk locus, wherein the SNP is rs922483 (SEQ ID NO: 13) and the SLE risk locus is *BLK*, wherein the variation is thymine at chromosomal location 11389322 on human chromosome 8.

67. The method of any one of claims 59-66, wherein the detecting comprises carrying out a process selected from a primer extension assay; an allele-specific primer extension assay; an allele-specific nucleotide incorporation assay; an allele-specific oligonucleotide hybridization assay; a 5' nuclease assay; an assay employing molecular beacons; and an oligonucleotide ligation assay.



2 / 12






FIG. 2A


3 / 12




4 / 12





5 / 12




6 / 12





7 / 12

**FIG. 2F****FIG. 3**





## FIG. 4



9 / 12

**FIG. 5A****FIG. 5B**


10 / 12

**FIG. 5C****FIG. 5D**

11 / 12

**FIG. 5E****FIG. 5F**

12 / 12



rs922483:

CTCTGATCGCAGACCGGGGGTGC[C/T]ACCTCTGTCTGCT  
GCCGGCAGAAAG

(SEQ ID No.13)

**FIG. 7**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2010/051589

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl.

C12Q 1/68 (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
 EPODOC, WPI, MEDLINE, HCAPLUS & BIOSIS keywords: BLK, TNIP1, PRDM1, JAZF1, UHRF1BP1, IL10, IFIH1, CFB, CLEC16A, IL12B, SH2B3, SNP, SLE, Lupus and other like terms  
 GENOMEQUEST: SEQ ID NO: 13, 16, 18, 20, 22, 24, 68, 70, 72, 74 and 76

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/144761 A2 (GENENTECH, INC.) 27 November 2008 See Paragraphs [0002], [0011], [0014], [0015], [0239], [0241], [0264], Table 6, Examples 2 and 6	1-5, 10, 14-19, 24, 28-32, 37, 41-43, 45-47, 50, 51, 53-55, 58
A	DEL-POZO N et al., 'Lack of evidence of a role of XBP1 and PRDM1 polymorphisms in Spanish patients with immunoglobulin A deficiency', Human Immunology, 2009, vol. 70, pages 950-952 (Published online 6 September 2009). See Abstract, Table 1, Page 951 and Discussion	

Further documents are listed in the continuation of Box C  See patent family annex

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance  
 "E" earlier application or patent but published on or after the international filing date  
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
 "O" document referring to an oral disclosure, use, exhibition or other means  
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art  
 "&" document member of the same patent family

Date of the actual completion of the international search  
17 January 2011Date of mailing of the international search report  
31 JAN 2011Name and mailing address of the ISA/AU  
 AUSTRALIAN PATENT OFFICE  
 PO BOX 200, WODEN ACT 2606, AUSTRALIA  
 E-mail address: pct@ipaaustralia.gov.au  
 Facsimile No. +61 2 6283 7999Authorized officer  
**Esther Ng**  
 AUSTRALIAN PATENT OFFICE  
 (ISO 9001 Quality Certified Service)  
 Telephone No : +61 2 6283 3129

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2010/051589

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	UNOKI M et al., 'ICBP90, an E2F-1 target, recruits HDAC1 and binds to methyl-CpG through its SRA domain', <i>Oncogene</i> , 2004, vol. 23, pages 7601-7610 See Pages 7605 and 7607, Figure 7	
X	WO 2001/011084 A1 (UAB RESEARCH FOUNDATION) 15 February 2001 See Page 3, paragraph 3, Page 5, paragraph 2 and Figure 1	2-5, 14, 16, 18, 19, 29, 31, 32, 41, 43, 46, 47, 54, 55, 58
A	LIU S et al., 'IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells', <i>Human Molecular Genetics</i> , 2009, vol. 18, pages 358-365, (Published online 16 October, 2008) See Abstract, Page 359, column 1, last paragraph, material and methods and Discussion	
X	WO 2002/018414 A2 (GENAISANCE PHARMACEUTICALS, INC.) 7 March 2002 See Abstract and Page 6, paragraph 3	6-9, 14, 20-23, 33-36, 41, 44, 48, 49, 52, 56-58
A	INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM, 'The expanding genetic overlap between multiple sclerosis and type 1 diabetes', <i>Genes and Immunity</i> , 2009, vol. 10, pages 11-14 (Published online, 6 November 2008) See Page 11, column 1, paragraph 1, Page 13, column 1, paragraph 3 and Table 2	
A	WO 2008/033239 A2 (APPLERA) 20 March 2008 See Page 7, Paragraph 3, Page 8, Page 160, Table 2	
A	PRAHALAD S et al., 'Variants in TNFAIP3, STAT4, and C12orf30 Loci Associated with multiple autoimmune Diseases are also Associated with Juvenile Idiopathic arthritis', <i>Arthritis and Rheumatism</i> , July 2009, vol. 60, pages 2124-2130 See Materials and methods, Page 2125, column 2, paragraph 2, Page 2126, column 1, last paragraph	
P, X	GATEVA V et al., 'A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus', <i>Nature Genetics</i> , 2009, vol. 41, pages 1228-1233 (published online 18 October 2009). See Table 2, 3 and Page 1232, column 2, paragraphs 2-4	1-14
A	CHONG WP et al., 'Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus', <i>Genes and Immunity</i> , 2004, vol. 5, Pages 484-492	

A	GIBSON et al AW et al., 'Novel Single Nucleotide Polymorphisms in the Distal IL-10 production and enhance the risk of Systemic Lupus Erythematosus', Journal of Immunology, 2001, vol. 166, pages 3915-3922	
---	---	--

**INTERNATIONAL SEARCH REPORT**

International application No.

**PCT/US2010/051589****Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing filed or furnished:
  - a. (means)  
 on paper  
 in electronic form
  - b. (time)  
 in the international application as filed  
 together with the international application in electronic form  
 subsequently to this Authority for the purposes of search
2.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

The sequences searched were based on a sequence listing filed after a request was made.

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US2010/051589

**Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

2.  Claims Nos.:

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3.  Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

See Supplemental Box I

1.  As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2.  As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3.  As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: 1, 15, 28, 42, 45, 50 and 53 (completely) and claims 2-14, 16-27, 29-41, 43, 44, 46-49, 51, 52 and 54-67 (in part) where they relate to inventions 1-6 and 28-32

4.  No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

No protest accompanied the payment of additional search fees.

**Supplemental Box I**

(To be used when the space in any of Boxes I to IV is not sufficient)

**Continuation of Box No III:**

The international application does not comply with the requirements of unity of invention because it does not relate to one invention or to a group of inventions so linked as to form a single general inventive concept.

PCT Rule 13.2 states that where a group of inventions is claimed in one and the same international application, the requirement of unity of invention referred to in Rule 13.1 shall be fulfilled only where there is a technical relationship among those inventions involving one or more of the same corresponding special technical features. Rule 13.2 states that the expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

In assessing whether there is more than one invention claimed, I have given consideration to those features which can be considered to potentially distinguish the claimed combination of features from the prior art. Where different claims have different distinguishing features they define different inventions.

The International Searching Authority has found that there are 32 different inventions as follows:

**Invention 1**

Claims 1, 15, 28, 42, 45, 50 and 53 (completely) and claims 10-12, 14, 24-26, 37-39, 41, 58, 62, 66 and 67 (in part) are directed to a method of identifying lupus by detecting the presence of a variation in the BLK locus at a nucleotide position corresponding to the SNP rs922483 (SEQ ID NO: 13). A method of detecting the SNP rs922483 and using its association with SLE for predicting responsiveness to therapy in lupus patients, diagnosing/prognosing lupus, treating lupus patients, selecting a patient for treatment, for manufacturing lupus therapeutic agents and assessing risk of developing lupus are considered to define a first distinguishing feature.

**Inventions 2-27**

Claims 2-5, 10, 12-14, 16-19, 24, 26, 27, 29-32, 37, 39, 40, 41, 43, 46, 47, 51, 54, 55 and 58-67 (in part) are directed to a method of identifying lupus by detecting the presence of a variation at a nucleotide position corresponding to a SNP at a SLE risk locus as set forth in Table 4. A method of detecting each of the SNP at TNIP1, PRDM1, JAZF1, UHRF1BP1, IL10 and other SLE risk loci indicated in table 4, and the use of their association with SLE for diagnostic/prognostic and therapeutic applications for lupus are considered to define a second to twenty seventh distinguishing feature, wherein the detection of each SNP at each locus is considered to define a separate distinguishing feature.

**Inventions 28-32**

Claims 6-9, 11-14, 20-23, 25-27, 33-36, 38-41, 44, 48, 49, 52 and 56-67 (in part) are directed to a method of identifying lupus by detecting the presence of a variation at a nucleotide position corresponding to a SNP at a SLE risk locus as set forth in Table 6. A method of detecting each of the SNP at IFIH1, CFB, CLEC16A, IL12B and SH2B3, and the use of their association with SLE for diagnostic/prognostic and therapeutic applications for lupus are considered to define a twenty eighth to thirty second distinguishing feature, wherein the detection of each SNP at each locus is considered to define a separate distinguishing feature.

The only feature common to all of the claims is the identification of risk loci and polymorphisms associated with lupus. However this concept is not novel in light of either of the following documents:

CHONG WP et al., 'Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus', Genes and Immunity, 2004, vol. 5, pages 484-492

GIBSON AW et al., 'Novel Single Nucleotide Polymorphisms in the Distal IL-10 Promoter Affect IL-10 production and Enhance the risk of Systemic Lupus Erythematosus', Journal of Immunology, 2001, vol. 166, pages 3915-3922

.../Continued in Supplemental Box II

**Supplemental Box II**

(To be used when the space in any of Boxes I to VIII is not sufficient)

**Continuation of Supplemental Box No I:**

Each of these documents discloses the association of single nucleotide polymorphisms (SNP) in the IL-10 loci with Systemic lupus erythematosus (SLE) susceptibility and disease. CHONG WP et al. discloses the association of the SNP -592 in the IL-10 promoter, with SLE predisposition in Hong Kong Chinese (Page 487, col. 2, paragraph 2). GIBSON AW et al., discloses a significant difference in the genotype distribution at the SNPs (-3575 and -2763) within the IL-10 promoter, between normal patients and African-Americans with SLE and its association with SLE disease susceptibility (Abstract and page 3920, col. 1, paragraph 3).

This means that the common feature cannot constitute a special technical feature within the meaning of PCT Rule 13.2, second sentence, since it makes no contribution over the prior art.

As a result of the common feature not satisfying the requirement for being a special technical feature, it follows that it cannot provide the necessary technical relationship between the identified inventions. Therefore the claims do not satisfy the requirement of unity of invention *a posteriori*.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2010/051589**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report			Patent Family Member				
WO	2008144761	AU	2008254582	CA	2690608	EP	2158335
		KR	20100021612	MX	2009012531		
WO	0111084	AU	65346/00				
WO	0218414	AU	86949/01				
WO	2008033239	EP	2064345	US	2008108713		

Due to data integration issues this family listing may not include 10 digit Australian applications filed since May 2001.

END OF ANNEX